{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T00:44:30Z","timestamp":1792975470585,"version":"4.5.0"},"reference-count":264,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:00:00Z","timestamp":1767139200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"DOI":"10.1186\/s12964-025-02632-y","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T23:33:18Z","timestamp":1767137598000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Immune cell-based therapies for solid tumors, current challenges and therapeutic advances"],"prefix":"10.1186","volume":"24","author":[{"given":"Shukoofeh","family":"Torabi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Yekzaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soroush","family":"Taherkhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negin","family":"Talachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roya","family":"Khoshravesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arezoo","family":"Khosravi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahsa","family":"Salehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Zarrabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massoud","family":"Vosough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,31]]},"reference":[{"issue":"1","key":"2632_CR1","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41392-024-01848-7","volume":"9","author":"S Zhang","year":"2024","unstructured":"Zhang S, Xiao X, Yi Y, Wang X, Zhu L, Shen Y, et al. Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets. Signal Transduct Target Therapy. 2024;9(1):149.","journal-title":"Signal Transduct Target Therapy"},{"issue":"2","key":"2632_CR2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nrc.2016.138","volume":"17","author":"T Otto","year":"2017","unstructured":"Otto T, Sicinski P. Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer. 2017;17(2):93\u2013115.","journal-title":"Nat Rev Cancer"},{"key":"2632_CR3","doi-asserted-by":"publisher","first-page":"205031212110343","DOI":"10.1177\/20503121211034366","volume":"9","author":"DT Debela","year":"2021","unstructured":"Debela DT, Muzazu SG, Heraro KD, Ndalama MT, Mesele BW, Haile DC, et al. New approaches and procedures for cancer treatment: current perspectives. SAGE Open Med. 2021;9:20503121211034366.","journal-title":"SAGE Open Med"},{"issue":"1","key":"2632_CR4","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","volume":"9","author":"B Liu","year":"2024","unstructured":"Liu B, Zhou H, Tan L, Siu KTH, Guan X-Y. Exploring treatment options in cancer: tumor treatment strategies. Signal Transduct Target Therapy. 2024;9(1):175.","journal-title":"Signal Transduct Target Therapy"},{"issue":"1","key":"2632_CR5","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12943-023-01867-y","volume":"22","author":"Y Mai","year":"2023","unstructured":"Mai Y, Su J, Yang C, Xia C, Fu L. The strategies to cure cancer patients by eradicating cancer stem-like cells. Mol Cancer. 2023;22(1):171.","journal-title":"Mol Cancer"},{"key":"2632_CR6","doi-asserted-by":"publisher","first-page":"1517959","DOI":"10.3389\/fimmu.2025.1517959","volume":"16","author":"J Yu","year":"2025","unstructured":"Yu J, Fu L, Wu R, Che L, Liu G, Ran Q, et al. Immunocytes in the tumor microenvironment: recent updates and interconnections. Front Immunol. 2025;16:1517959.","journal-title":"Front Immunol"},{"issue":"9","key":"2632_CR7","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1111\/jphp.12593","volume":"68","author":"H Siahmansouri","year":"2016","unstructured":"Siahmansouri H, Somi MH, Babaloo Z, Baradaran B, Jadidi-Niaragh F, Atyabi F, et al. Effects of HMGA2 SiRNA and doxorubicin dual delivery by Chitosan nanoparticles on cytotoxicity and gene expression of HT-29 colorectal cancer cell line. J Pharm Pharmacol. 2016;68(9):1119\u201330.","journal-title":"J Pharm Pharmacol"},{"key":"2632_CR8","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.biopha.2016.05.034","volume":"82","author":"H Shali","year":"2016","unstructured":"Shali H, Ahmadi M, Kafil HS, Dorosti A, Yousefi M. IGF1R and c-met as therapeutic targets for colorectal cancer. Biomed Pharmacother. 2016;82:528\u201336.","journal-title":"Biomed Pharmacother"},{"key":"2632_CR9","doi-asserted-by":"publisher","first-page":"954992","DOI":"10.3389\/fimmu.2022.954992","volume":"13","author":"MT Bilotta","year":"2022","unstructured":"Bilotta MT, Antignani A, Fitzgerald DJ. Managing the TME to improve the efficacy of cancer therapy. Front Immunol. 2022;13:954992.","journal-title":"Front Immunol"},{"key":"2632_CR10","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s13402-018-0388-2","volume":"41","author":"P Nilendu","year":"2018","unstructured":"Nilendu P, Sarode SC, Jahagirdar D, Tandon I, Patil S, Sarode GS, et al. Mutual concessions and compromises between stromal cells and cancer cells: driving tumor development and drug resistance. Cell Oncol. 2018;41:353\u201367.","journal-title":"Cell Oncol"},{"issue":"4","key":"2632_CR11","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41571-020-0338-6","volume":"17","author":"D Romero","year":"2020","unstructured":"Romero D. B cells and TLSs facilitate a response to ICI. Nat Reviews Clin Oncol. 2020;17(4):195.","journal-title":"Nat Reviews Clin Oncol"},{"issue":"1","key":"2632_CR12","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1146\/annurev-immunol-101220-015603","volume":"40","author":"SM Downs-Canner","year":"2022","unstructured":"Downs-Canner SM, Meier J, Vincent BG, Serody JS. B cell function in the tumor microenvironment. Annu Rev Immunol. 2022;40(1):169\u201393.","journal-title":"Annu Rev Immunol"},{"key":"2632_CR13","doi-asserted-by":"publisher","first-page":"1352805","DOI":"10.3389\/fimmu.2024.1352805","volume":"15","author":"V Albarr\u00e1n","year":"2024","unstructured":"Albarr\u00e1n V, San Rom\u00e1n M, Pozas J, Chamorro J, Rosero DI, Guerrero P, et al. Adoptive T cell therapy for solid tumors: current landscape and future challenges. Front Immunol. 2024;15:1352805.","journal-title":"Front Immunol"},{"key":"2632_CR14","doi-asserted-by":"publisher","first-page":"1493346","DOI":"10.3389\/fphar.2025.1493346","volume":"16","author":"W He","year":"2025","unstructured":"He W, Cui K, Farooq MA, Huang N, Zhu S, Jiang D, et al. TCR-T cell therapy for solid tumors: challenges and emerging solutions. Front Pharmacol. 2025;16:1493346.","journal-title":"Front Pharmacol"},{"issue":"17","key":"2632_CR15","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.3390\/cancers17172898","volume":"17","author":"S Rafii","year":"2025","unstructured":"Rafii S, Mukherji D, Komaranchath AS, Khalil C, Iqbal F, Abdelwahab SI, et al. Advancing CAR T-cell therapy in solid tumors: current landscape and future directions. Cancers. 2025;17(17):2898.","journal-title":"Cancers"},{"key":"2632_CR16","doi-asserted-by":"publisher","first-page":"1466266","DOI":"10.3389\/fimmu.2024.1466266","volume":"15","author":"D Zhu","year":"2024","unstructured":"Zhu D, Ren X, Xie W, Chen J, Liang S, Jiang M, et al. Potential of gamma\/delta T cells for solid tumor immunotherapy. Front Immunol. 2024;15:1466266.","journal-title":"Front Immunol"},{"key":"2632_CR17","doi-asserted-by":"publisher","first-page":"1679271","DOI":"10.3389\/fimmu.2025.1679271","volume":"16","author":"J Brancewicz","year":"2025","unstructured":"Brancewicz J, Kucharzewska P. Emerging macrophage-based therapies for cancer: a review of preclinical and clinical advances. Front Immunol. 2025;16:1679271.","journal-title":"Front Immunol"},{"key":"2632_CR18","doi-asserted-by":"publisher","first-page":"1615760","DOI":"10.3389\/fimmu.2025.1615760","volume":"16","author":"A Morva","year":"2025","unstructured":"Morva A, Arroyo AB, Andreeva L, Tapia-Abell\u00e1n A, Luengo-Gil G. Unleashing the power of CAR-M therapy in solid tumors: a comprehensive review. Front Immunol. 2025;16:1615760.","journal-title":"Front Immunol"},{"issue":"23","key":"2632_CR19","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.3390\/cells14231858","volume":"14","author":"T Budagova","year":"2025","unstructured":"Budagova T, Efremova A, Maiak M, Goldshtein D. Strategies for the development of NK Cell-Based therapies for cancer treatment. Cells. 2025;14(23):1858.","journal-title":"Cells"},{"issue":"1","key":"2632_CR20","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12935-023-02923-9","volume":"23","author":"K Hadiloo","year":"2023","unstructured":"Hadiloo K, Tahmasebi S, Esmaeilzadeh A. CAR-NKT cell therapy: a new promising paradigm of cancer immunotherapy. Cancer Cell Int. 2023;23(1):86.","journal-title":"Cancer Cell Int"},{"key":"2632_CR21","doi-asserted-by":"publisher","first-page":"1621222","DOI":"10.3389\/fimmu.2025.1621222","volume":"16","author":"A Boucher","year":"2025","unstructured":"Boucher A, Anderson C, Hinman R, Kindschuh M, Fung J, Wang T, et al. Engineered human B cells targeting tumor-associated antigens exhibit antigen presentation and antibody-mediated functions. Front Immunol. 2025;16:1621222.","journal-title":"Front Immunol"},{"key":"2632_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102412","author":"Georgia Clayton","year":"2025","unstructured":"Clayton G, Toffoli EC, de Gruijl TD, van Kooyk Y. Dendritic cell immunotherapy advances for solid tumors: vaccination and modulation. Cell Rep Med. 2025. 1-27 https:\/\/doi.org\/10.1016\/j.xcrm.2025.102412","journal-title":"Cell Reports Medicine"},{"issue":"1","key":"2632_CR23","first-page":"948098","volume":"2012","author":"N-B Hao","year":"2012","unstructured":"Hao N-B, L\u00fc M-H, Fan Y-H, Cao Y-L, Zhang Z-R, Yang S-M. Macrophages in tumor microenvironments and the progression of tumors. J Immunol Res. 2012;2012(1):948098.","journal-title":"J Immunol Res"},{"key":"2632_CR24","doi-asserted-by":"publisher","DOI":"10.34172\/apb.025.43855","author":"Wahyu Widowati","year":"2025","unstructured":"Widowati Wahyu. M2 Macrophages-Based Immunotherapy: A New Therapeutic Approach in Liver Fibrosis. Advanced Pharmaceutical Bulletin. 2025;15(2):314-325.\u00a0https:\/\/doi.org\/10.34172\/apb.025.43855","journal-title":"Advanced Pharmaceutical Bulletin"},{"key":"2632_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105502","author":"Chuncha Bao","year":"2025","unstructured":"Bao C, Ma Q, Ying X, Wang F, Hou Y, Wang D. Histone lactylation in macrophage biology and disease: from plasticity regulation to therapeutic Implications. eBioMedicine, 111. Article ID. 2025;105502. 1-17. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105502","journal-title":"eBioMedicine"},{"issue":"1","key":"2632_CR26","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13058-024-01887-6","volume":"26","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Zhong F, Liu L. Single-cell transcriptional atlas of tumor-associated macrophages in breast cancer. Breast Cancer Res. 2024;26(1):129.","journal-title":"Breast Cancer Res"},{"issue":"13","key":"2632_CR27","doi-asserted-by":"publisher","first-page":"6995","DOI":"10.3390\/ijms22136995","volume":"22","author":"AJ Boutilier","year":"2021","unstructured":"Boutilier AJ, Elsawa SF. Macrophage polarization States in the tumor microenvironment. Int J Mol Sci. 2021;22(13):6995.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"2632_CR28","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1007\/s12094-021-02652-3","volume":"23","author":"H Kuroda","year":"2021","unstructured":"Kuroda H, Jamiyan T, Yamaguchi R, Kakumoto A, Abe A, Harada O, et al. Tumor microenvironment in triple-negative breast cancer: the correlation of tumor-associated macrophages and tumor-infiltrating lymphocytes. Clin Transl Oncol. 2021;23(12):2513\u201325.","journal-title":"Clin Transl Oncol"},{"issue":"1","key":"2632_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2007.07.004","volume":"66","author":"P Allavena","year":"2008","unstructured":"Allavena P, Sica A, Solinas G, Porta C, Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol\/Hematol. 2008;66(1):1\u20139.","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"12","key":"2632_CR30","doi-asserted-by":"publisher","first-page":"6560","DOI":"10.3390\/ijms22126560","volume":"22","author":"H Wang","year":"2021","unstructured":"Wang H, Yung MM, Ngan HY, Chan KK, Chan DW. The impact of the tumor microenvironment on macrophage polarization in cancer metastatic progression. Int J Mol Sci. 2021;22(12):6560.","journal-title":"Int J Mol Sci"},{"key":"2632_CR31","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.3389\/fimmu.2020.01731","volume":"11","author":"K Wu","year":"2020","unstructured":"Wu K, Lin K, Li X, Yuan X, Xu P, Ni P, et al. Redefining tumor-associated macrophage subpopulations and functions in the tumor microenvironment. Front Immunol. 2020;11:1731.","journal-title":"Front Immunol"},{"key":"2632_CR32","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3389\/fphys.2013.00157","volume":"4","author":"JS Russell","year":"2013","unstructured":"Russell JS, Brown JM. The irradiated tumor microenvironment: role of tumor-associated macrophages in vascular recovery. Front Physiol. 2013;4:157.","journal-title":"Front Physiol"},{"key":"2632_CR33","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.canlet.2016.01.043","volume":"387","author":"T Wu","year":"2017","unstructured":"Wu T, Dai Y. Tumor microenvironment and therapeutic response. Cancer Lett. 2017;387:61\u20138.","journal-title":"Cancer Lett"},{"issue":"14","key":"2632_CR34","doi-asserted-by":"publisher","first-page":"5728","DOI":"10.1158\/0008-5472.CAN-09-4672","volume":"70","author":"K Movahedi","year":"2010","unstructured":"Movahedi K, Laoui D, Gysemans C, Baeten M, Stang\u00e9 G, Van den Bossche J, et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C (high) monocytes. Cancer Res. 2010;70(14):5728\u201339.","journal-title":"Cancer Res"},{"key":"2632_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.110171","author":"Xenia Geeraerts","year":"2021","unstructured":"Geeraerts X, Fernandez-Garcia J, Hartmann FJ, de Goede KE, Martens L, Elkrim Y et al. Macrophages are metabolically heterogeneous within the tumor microenvironment. Cell Rep. 2021;37(13), 1-29 . https:\/\/doi.org\/10.1016\/j.celrep.2021.110171","journal-title":"Cell reports"},{"issue":"8","key":"2632_CR36","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s00018-022-04413-z","volume":"79","author":"W Wei","year":"2022","unstructured":"Wei W, Zhang Y, Song Q, Zhang Q, Zhang X, Liu X, et al. Transmissible ER stress between macrophages and tumor cells configures tumor microenvironment. Cell Mol Life Sci. 2022;79(8):403.","journal-title":"Cell Mol Life Sci"},{"key":"2632_CR37","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.molimm.2017.12.003","volume":"110","author":"KB Long","year":"2019","unstructured":"Long KB, Collier AI, Beatty GL. Macrophages: key orchestrators of a tumor microenvironment defined by therapeutic resistance. Mol Immunol. 2019;110:3\u201312.","journal-title":"Mol Immunol"},{"key":"2632_CR38","doi-asserted-by":"publisher","first-page":"4603","DOI":"10.1016\/j.csbj.2021.08.019","volume":"19","author":"H Zhang","year":"2021","unstructured":"Zhang H, Luo Y-B, Wu W, Zhang L, Wang Z, Dai Z, et al. The molecular feature of macrophages in tumor immune microenvironment of glioma patients. Comput Struct Biotechnol J. 2021;19:4603\u201318.","journal-title":"Comput Struct Biotechnol J"},{"issue":"2","key":"2632_CR39","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.canlet.2014.11.004","volume":"358","author":"W Mou","year":"2015","unstructured":"Mou W, Xu Y, Ye Y, Chen S, Li X, Gong K, et al. Expression of Sox2 in breast cancer cells promotes the recruitment of M2 macrophages to tumor microenvironment. Cancer Lett. 2015;358(2):115\u201323.","journal-title":"Cancer Lett"},{"issue":"5","key":"2632_CR40","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.3390\/ijms23052509","volume":"23","author":"E Codrici","year":"2022","unstructured":"Codrici E, Popescu I-D, Tanase C, Enciu A-M. Friends with benefits: chemokines, glioblastoma-associated microglia\/macrophages, and tumor microenvironment. Int J Mol Sci. 2022;23(5):2509.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2632_CR41","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/path.2602","volume":"219","author":"S Hallam","year":"2009","unstructured":"Hallam S, Escorcio-Correia M, Soper R, Schultheiss A, Hagemann T. Activated macrophages in the tumour microenvironment\u2014dancing to the tune of TLR and NF\u2010\u03baB. J Pathology: J Pathological Soc Great Br Irel. 2009;219(2):143\u201352.","journal-title":"J Pathology: J Pathological Soc Great Br Irel"},{"issue":"23","key":"2632_CR42","doi-asserted-by":"publisher","first-page":"5591","DOI":"10.1242\/jcs.116392","volume":"125","author":"FR Balkwill","year":"2012","unstructured":"Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. J Cell Sci. 2012;125(23):5591\u20136.","journal-title":"J Cell Sci"},{"key":"2632_CR43","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3389\/fimmu.2014.00127","volume":"5","author":"E Van Overmeire","year":"2014","unstructured":"Van Overmeire E, Laoui D, Keirsse J, Van Ginderachter JA, Sarukhan A. Mechanisms driving macrophage diversity and specialization in distinct tumor microenvironments and parallelisms with other tissues. Front Immunol. 2014;5:127.","journal-title":"Front Immunol"},{"issue":"4","key":"2632_CR44","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/s41416-024-02715-6","volume":"131","author":"JH Rannikko","year":"2024","unstructured":"Rannikko JH, Hollmen M. Clinical landscape of macrophage-reprogramming cancer immunotherapies. Br J Cancer. 2024;131(4):627\u201340.","journal-title":"Br J Cancer"},{"key":"2632_CR45","doi-asserted-by":"publisher","first-page":"1295257","DOI":"10.3389\/fimmu.2023.1295257","volume":"14","author":"U Basak","year":"2023","unstructured":"Basak U, Sarkar T, Mukherjee S, Chakraborty S, Dutta A, Dutta S, et al. Tumor-associated macrophages: an effective player of the tumor microenvironment. Front Immunol. 2023;14:1295257.","journal-title":"Front Immunol"},{"issue":"4","key":"2632_CR46","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/s41419-024-06616-7","volume":"15","author":"S Yang","year":"2024","unstructured":"Yang S, Wang Y, Jia J, Fang Y, Yang Y, Yuan W, et al. Advances in engineered macrophages: a new frontier in cancer immunotherapy. Cell Death Dis. 2024;15(4):238.","journal-title":"Cell Death Dis"},{"issue":"2","key":"2632_CR47","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1089\/hum.2016.060","volume":"28","author":"KW Moyes","year":"2017","unstructured":"Moyes KW, Lieberman NA, Kreuser SA, Chinn H, Winter C, Deutsch G, et al. Genetically engineered macrophages: a potential platform for cancer immunotherapy. Hum Gene Ther. 2017;28(2):200\u201315.","journal-title":"Hum Gene Ther"},{"key":"2632_CR48","doi-asserted-by":"publisher","first-page":"111605","DOI":"10.1016\/j.biopha.2021.111605","volume":"139","author":"Y Chen","year":"2021","unstructured":"Chen Y, Yu Z, Tan X, Jiang H, Xu Z, Fang Y, et al. CAR-macrophage: A new immunotherapy candidate against solid tumors. Biomed Pharmacother. 2021;139:111605.","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"2632_CR49","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41577-022-00737-w","volume":"23","author":"S Goswami","year":"2023","unstructured":"Goswami S, Anandhan S, Raychaudhuri D, Sharma P. Myeloid cell-targeted therapies for solid tumours. Nat Rev Immunol. 2023;23(2):106\u201320.","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"2632_CR50","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1016\/j.ymthe.2022.04.015","volume":"30","author":"H Qian","year":"2022","unstructured":"Qian H, Fu Y, Guo M, Chen Y, Zhang D, Wei Y, et al. Dual-aptamer-engineered M1 macrophage with enhanced specific targeting and checkpoint blocking for solid-tumor immunotherapy. Mol Ther. 2022;30(8):2817\u201327.","journal-title":"Mol Ther"},{"issue":"12","key":"2632_CR51","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/nrd.2018.169","volume":"17","author":"L Cassetta","year":"2018","unstructured":"Cassetta L, Pollard JW. Targeting macrophages: therapeutic approaches in cancer. Nat Rev Drug Discovery. 2018;17(12):887\u2013904.","journal-title":"Nat Rev Drug Discovery"},{"issue":"10","key":"2632_CR52","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1158\/2326-6066.CIR-22-0030","volume":"10","author":"M Cannac","year":"2022","unstructured":"Cannac M, Nikolic J, Benaroch P. Cancer immunotherapies based on genetically engineered macrophages. Cancer Immunol Res. 2022;10(10):1156\u201366.","journal-title":"Cancer Immunol Res"},{"key":"2632_CR53","doi-asserted-by":"publisher","first-page":"786913","DOI":"10.3389\/fonc.2021.786913","volume":"11","author":"X Ding","year":"2022","unstructured":"Ding X, Sun X, Cai H, Wu L, Liu Y, Zhao Y, et al. Engineering macrophages via nanotechnology and genetic manipulation for cancer therapy. Front Oncol. 2022;11:786913.","journal-title":"Front Oncol"},{"key":"2632_CR54","doi-asserted-by":"publisher","first-page":"1291619","DOI":"10.3389\/fimmu.2023.1291619","volume":"14","author":"Y Liang","year":"2023","unstructured":"Liang Y, Xu Q, Gao Q. Advancing CAR-based immunotherapies in solid tumors: CAR-macrophages and neutrophils. Front Immunol. 2023;14:1291619.","journal-title":"Front Immunol"},{"issue":"1","key":"2632_CR55","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","volume":"22","author":"KM Maalej","year":"2023","unstructured":"Maalej KM, Merhi M, Inchakalody VP, Mestiri S, Alam M, Maccalli C, et al. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol Cancer. 2023;22(1):20.","journal-title":"Mol Cancer"},{"key":"2632_CR56","doi-asserted-by":"publisher","first-page":"114354","DOI":"10.1016\/j.bcp.2020.114354","volume":"183","author":"N Cheng","year":"2021","unstructured":"Cheng N, Bai X, Shu Y, Ahmad O, Shen P. Targeting tumor-associated macrophages as an antitumor strategy. Biochem Pharmacol. 2021;183:114354.","journal-title":"Biochem Pharmacol"},{"issue":"16","key":"2632_CR57","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1021\/acs.accounts.4c00293","volume":"57","author":"P Liu","year":"2024","unstructured":"Liu P, Hu Q. Engineering cells for cancer therapy. Acc Chem Res. 2024;57(16):2358\u201371.","journal-title":"Acc Chem Res"},{"issue":"1","key":"2632_CR58","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1186\/s12951-021-01123-9","volume":"19","author":"C Zhang","year":"2021","unstructured":"Zhang C, Li D, Hu H, Wang Z, An J, Gao Z, et al. Engineered extracellular vesicles derived from primary M2 macrophages with anti-inflammatory and neuroprotective properties for the treatment of spinal cord injury. J Nanobiotechnol. 2021;19(1):373.","journal-title":"J Nanobiotechnol"},{"issue":"5","key":"2632_CR59","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1002\/oby.20679","volume":"22","author":"ME Kranendonk","year":"2014","unstructured":"Kranendonk ME, Visseren FL, van Balkom BW, Nolte-\u2018t Hoen EN, van Herwaarden JA, de Jager W, et al. Human adipocyte extracellular vesicles in reciprocal signaling between adipocytes and macrophages. Obesity. 2014;22(5):1296\u2013308.","journal-title":"Obesity"},{"issue":"1","key":"2632_CR60","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1074\/jbc.M115.694133","volume":"291","author":"B Saha","year":"2016","unstructured":"Saha B, Momen-Heravi F, Kodys K, Szabo G. MicroRNA cargo of extracellular vesicles from alcohol-exposed monocytes signals Naive monocytes to differentiate into M2 macrophages. J Biol Chem. 2016;291(1):149\u201359.","journal-title":"J Biol Chem"},{"issue":"12","key":"2632_CR61","doi-asserted-by":"publisher","first-page":"e2016","DOI":"10.1038\/cddis.2015.282","volume":"6","author":"H Moon","year":"2015","unstructured":"Moon H, Cao Y, Yang J, Lee J, Choi H, Jin Y. Lung epithelial cell-derived extracellular vesicles activate macrophage-mediated inflammatory responses via ROCK1 pathway. Cell Death Dis. 2015;6(12):e2016\u2013e.","journal-title":"Cell Death Dis"},{"issue":"3","key":"2632_CR62","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1002\/sctm.16-0363","volume":"6","author":"C Lo Sicco","year":"2017","unstructured":"Lo Sicco C, Reverberi D, Balbi C, Ulivi V, Principi E, Pascucci L, et al. Mesenchymal stem cell-derived extracellular vesicles as mediators of anti-inflammatory effects: endorsement of macrophage polarization. Stem Cells Translational Med. 2017;6(3):1018\u201328.","journal-title":"Stem Cells Translational Med"},{"issue":"17","key":"2632_CR63","doi-asserted-by":"publisher","first-page":"e2107394119","DOI":"10.1073\/pnas.2107394119","volume":"119","author":"M Tkach","year":"2022","unstructured":"Tkach M, Thalmensi J, Timperi E, Gueguen P, N\u00e9vo N, Grisard E, et al. Extracellular vesicles from triple negative breast cancer promote pro-inflammatory macrophages associated with better clinical outcome. Proc Natl Acad Sci. 2022;119(17):e2107394119.","journal-title":"Proc Natl Acad Sci"},{"issue":"5","key":"2632_CR64","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1007\/s10753-020-01236-7","volume":"43","author":"Y Shi","year":"2020","unstructured":"Shi Y, Luo P, Wang W, Horst K, Bl\u00e4sius F, Relja B, et al. M1 but not M0 extracellular vesicles induce polarization of RAW264. 7 macrophages via the TLR4-NF\u03baB pathway in vitro. Inflammation. 2020;43(5):1611\u20139.","journal-title":"Inflammation"},{"issue":"8","key":"2632_CR65","doi-asserted-by":"publisher","first-page":"e0237795","DOI":"10.1371\/journal.pone.0237795","volume":"15","author":"LA Arteaga-Blanco","year":"2020","unstructured":"Arteaga-Blanco LA, Mojoli A, Monteiro RQ, Sandim V, Menna-Barreto RF, Pereira-Dutra FS, et al. Characterization and internalization of small extracellular vesicles released by human primary macrophages derived from Circulating monocytes. PLoS ONE. 2020;15(8):e0237795.","journal-title":"PLoS ONE"},{"issue":"1","key":"2632_CR66","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1161\/ATVBAHA.117.309795","volume":"38","author":"M-A Nguyen","year":"2018","unstructured":"Nguyen M-A, Karunakaran D, Geoffrion M, Cheng HS, Tandoc K, Perisic Matic L, et al. Extracellular vesicles secreted by atherogenic macrophages transfer MicroRNA to inhibit cell migration. Arterioscler Thromb Vasc Biol. 2018;38(1):49\u201363.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"2632_CR67","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/med.21511","volume":"39","author":"MC Oca\u00f1a","year":"2019","unstructured":"Oca\u00f1a MC, Mart\u00ednez-Poveda B, Quesada AR, Medina M\u00c1. Metabolism within the tumor microenvironment and its implication on cancer progression: an ongoing therapeutic target. Med Res Rev. 2019;39(1):70\u2013113.","journal-title":"Med Res Rev"},{"issue":"2","key":"2632_CR68","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/pcmr.12736","volume":"32","author":"FV Almeida","year":"2019","unstructured":"Almeida FV, Douglass SM, Fane ME, Weeraratna AT. Bad company: microenvironmentally mediated resistance to targeted therapy in melanoma. Pigment Cell Melanoma Res. 2019;32(2):237\u201347.","journal-title":"Pigment Cell Melanoma Res"},{"key":"2632_CR69","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s00262-016-1820-y","volume":"65","author":"J Zong","year":"2016","unstructured":"Zong J, Keskinov AA, Shurin GV, Shurin MR. Tumor-derived factors modulating dendritic cell function. Cancer Immunol Immunother. 2016;65:821\u201333.","journal-title":"Cancer Immunol Immunother"},{"key":"2632_CR70","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s00018-016-2317-8","volume":"74","author":"M Tang","year":"2017","unstructured":"Tang M, Diao J, Cattral MS. Molecular mechanisms involved in dendritic cell dysfunction in cancer. Cell Mol Life Sci. 2017;74:761\u201376.","journal-title":"Cell Mol Life Sci"},{"issue":"12","key":"2632_CR71","first-page":"4778","volume":"92","author":"C Menetrier-Caux","year":"1998","unstructured":"Menetrier-Caux C, Montmain G, Dieu M, Bain C, Favrot M, Caux C, et al. Inhibition of the differentiation of dendritic cells from CD34\u2009+\u2009progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood J Am Soc Hematol. 1998;92(12):4778\u201391.","journal-title":"Blood J Am Soc Hematol"},{"issue":"11","key":"2632_CR72","doi-asserted-by":"publisher","first-page":"5479","DOI":"10.1158\/0008-5472.CAN-06-3963","volume":"67","author":"U Bharadwaj","year":"2007","unstructured":"Bharadwaj U, Li M, Zhang R, Chen C, Yao Q. Elevated interleukin-6 and G-CSF in human pancreatic cancer cell conditioned medium suppress dendritic cell differentiation and activation. Cancer Res. 2007;67(11):5479\u201388.","journal-title":"Cancer Res"},{"issue":"1","key":"2632_CR73","first-page":"430394","volume":"2011","author":"N Janikashvili","year":"2011","unstructured":"Janikashvili N, Bonnotte B, Katsanis E, Larmonier N. The dendritic cell-regulatory T lymphocyte crosstalk contributes to tumor\u2010induced tolerance. J Immunol Res. 2011;2011(1):430394.","journal-title":"J Immunol Res"},{"issue":"9","key":"2632_CR74","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/ni.2376","volume":"13","author":"S Chiba","year":"2012","unstructured":"Chiba S, Baghdadi M, Akiba H, Yoshiyama H, Kinoshita I, Dosaka-Akita H, et al. Tumor-infiltrating DCs suppress nucleic acid\u2013mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol. 2012;13(9):832\u201342.","journal-title":"Nat Immunol"},{"issue":"12","key":"2632_CR75","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/nri1498","volume":"4","author":"D Gabrilovich","year":"2004","unstructured":"Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol. 2004;4(12):941\u201352.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"2632_CR76","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1111\/j.1399-3046.2008.01066.x","volume":"13","author":"A Suminoe","year":"2009","unstructured":"Suminoe A, Matsuzaki A, Hattori H, Koga Y, Hara T. Immunotherapy with autologous dendritic cells and tumor antigens for children with refractory malignant solid tumors. Pediatr Transplant. 2009;13(6):746\u201353.","journal-title":"Pediatr Transplant"},{"issue":"1","key":"2632_CR77","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.canlet.2012.04.024","volume":"324","author":"N-C Jung","year":"2012","unstructured":"Jung N-C, Kim HJ, Kang M-S, Lee J-H, Song J-Y, Seo HG, et al. Photodynamic therapy-mediated DC immunotherapy is highly effective for the Inhibition of established solid tumors. Cancer Lett. 2012;324(1):58\u201365.","journal-title":"Cancer Lett"},{"key":"2632_CR78","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1007\/s00262-007-0325-0","volume":"56","author":"D-S Lim","year":"2007","unstructured":"Lim D-S, Kim J-H, Lee D-S, Yoon C-H, Bae Y-S. DC immunotherapy is highly effective for the Inhibition of tumor metastasis or recurrence, although it is not efficient for the eradication of established solid tumors. Cancer Immunol Immunother. 2007;56:1817\u201329.","journal-title":"Cancer Immunol Immunother"},{"key":"2632_CR79","doi-asserted-by":"publisher","first-page":"547653","DOI":"10.3389\/fcell.2020.547653","volume":"8","author":"R Ramezankhani","year":"2020","unstructured":"Ramezankhani R, Torabi S, Minaei N, Madani H, Rezaeiani S, Hassani SN, et al. Two decades of global progress in authorized advanced therapy medicinal products: an emerging revolution in therapeutic strategies. Front Cell Dev Biology. 2020;8:547653.","journal-title":"Front Cell Dev Biology"},{"key":"2632_CR80","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.omto.2019.03.007","volume":"13","author":"RA Belderbos","year":"2019","unstructured":"Belderbos RA, Aerts JG, Vroman H. Enhancing dendritic cell therapy in solid tumors with Immunomodulating conventional treatment. Mol Therapy-Oncolytics. 2019;13:67\u201381.","journal-title":"Mol Therapy-Oncolytics"},{"issue":"6","key":"2632_CR81","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41551-018-0250-x","volume":"2","author":"M Saxena","year":"2018","unstructured":"Saxena M, Balan S, Roudko V, Bhardwaj N. Towards superior dendritic-cell vaccines for cancer therapy. Nat Biomedical Eng. 2018;2(6):341\u20136.","journal-title":"Nat Biomedical Eng"},{"issue":"2","key":"2632_CR82","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2217\/cns.14.54","volume":"4","author":"A Hdeib","year":"2015","unstructured":"Hdeib A, Sloan AE. Dendritic cell immunotherapy for solid tumors: evaluation of the DCVax\u00ae platform in the treatment of glioblastoma multiforme. CNS Oncol. 2015;4(2):63\u20139.","journal-title":"CNS Oncol"},{"issue":"1","key":"2632_CR83","doi-asserted-by":"publisher","first-page":"5408","DOI":"10.1038\/s41467-019-13368-y","volume":"10","author":"CR Perez","year":"2019","unstructured":"Perez CR, De Palma M. Engineering dendritic cell vaccines to improve cancer immunotherapy. Nat Commun. 2019;10(1):5408.","journal-title":"Nat Commun"},{"issue":"3","key":"2632_CR84","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/nmeth.4579","volume":"15","author":"ML Squadrito","year":"2018","unstructured":"Squadrito ML, Cianciaruso C, Hansen SK, De Palma M. EVIR: chimeric receptors that enhance dendritic cell cross-dressing with tumor antigens. Nat Methods. 2018;15(3):183\u20136.","journal-title":"Nat Methods"},{"issue":"39","key":"2632_CR85","doi-asserted-by":"publisher","first-page":"33532","DOI":"10.1021\/acsami.8b10081","volume":"10","author":"X Yang","year":"2018","unstructured":"Yang X, Lian K, Meng T, Liu X, Miao J, Tan Y, et al. Immune adjuvant targeting micelles allow efficient dendritic cell migration to lymph nodes for enhanced cellular immunity. ACS Appl Mater Interfaces. 2018;10(39):33532\u201344.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"22","key":"2632_CR86","first-page":"4501","volume":"116","author":"W Hobo","year":"2010","unstructured":"Hobo W, Maas F, Adisty N, de Witte T, Schaap N, van der Voort R, et al. SiRNA Silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen\u2013specific CD8\u2009+\u2009T cells. Blood J Am Soc Hematol. 2010;116(22):4501\u201311.","journal-title":"Blood J Am Soc Hematol"},{"issue":"5","key":"2632_CR87","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","volume":"31","author":"S Spranger","year":"2017","unstructured":"Spranger S, Dai D, Horton B, Gajewski TF. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell. 2017;31(5):711\u201323. e4.","journal-title":"Cancer Cell"},{"issue":"12","key":"2632_CR88","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1007\/s11864-023-01143-7","volume":"24","author":"P Li","year":"2023","unstructured":"Li P, Jia L, Bian X, Tan S. Application of engineered dendritic cell vaccines in cancer immunotherapy: challenges and opportunities. Curr Treat Options Oncol. 2023;24(12):1703\u201319.","journal-title":"Curr Treat Options Oncol"},{"issue":"12","key":"2632_CR89","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/nri1246","volume":"3","author":"ML Kapsenberg","year":"2003","unstructured":"Kapsenberg ML. Dendritic-cell control of pathogen-driven T-cell polarization. Nat Rev Immunol. 2003;3(12):984\u201393.","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"2632_CR90","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1111\/cas.13735","volume":"109","author":"N Seo","year":"2018","unstructured":"Seo N, Akiyoshi K, Shiku H. Exosome-mediated regulation of tumor immunology. Cancer Sci. 2018;109(10):2998\u20133004.","journal-title":"Cancer Sci"},{"issue":"3","key":"2632_CR91","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1189\/jlb.0206094","volume":"80","author":"N Chaput","year":"2006","unstructured":"Chaput N, Flament C, Viaud S, Taieb J, Roux S, Spatz A, et al. Dendritic cell derived-exosomes: biology and clinical implementations. J Leukoc Biol. 2006;80(3):471\u20138.","journal-title":"J Leukoc Biol"},{"issue":"12","key":"2632_CR92","doi-asserted-by":"publisher","first-page":"3334","DOI":"10.1002\/eji.201142268","volume":"42","author":"S Gulinelli","year":"2012","unstructured":"Gulinelli S, Salaro E, Vuerich M, Bozzato D, Pizzirani C, Bolognesi G, et al. IL-18 associates to microvesicles shed from human macrophages by a LPS\/TLR\u20104 independent mechanism in response to P2X receptor stimulation. Eur J Immunol. 2012;42(12):3334\u201345.","journal-title":"Eur J Immunol"},{"key":"2632_CR93","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/j.ijbiomac.2018.02.034","volume":"113","author":"S Chen","year":"2018","unstructured":"Chen S, Lv M, Fang S, Ye W, Gao Y, Xu Y. Poly (I: C) enhanced anti-cervical cancer immunities induced by dendritic cells-derived exosomes. Int J Biol Macromol. 2018;113:1182\u20137.","journal-title":"Int J Biol Macromol"},{"key":"2632_CR94","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s12031-015-0506-9","volume":"56","author":"N Bu","year":"2015","unstructured":"Bu N, Wu H, Zhang G, Zhan S, Zhang R, Sun H, et al. Exosomes from dendritic cells loaded with chaperone-rich cell lysates elicit a potent T cell immune response against intracranial glioma in mice. J Mol Neurosci. 2015;56:631\u201343.","journal-title":"J Mol Neurosci"},{"key":"2632_CR95","doi-asserted-by":"publisher","DOI":"10.1111\/imm.70033","author":"Jonathan Shpigelman","year":"2025","unstructured":"Shpigelman J, Rao K. Dendritic Cell-Derived Extracellular Vesicles as Therapeutic Cancer Vaccines: Mechanisms and Optimization Strategies. Immunology. 2025. 1-13 https:\/\/doi.org\/10.1111\/imm.70033","journal-title":"Immunology"},{"key":"2632_CR96","doi-asserted-by":"publisher","first-page":"490","DOI":"10.3389\/fimmu.2013.00490","volume":"4","author":"J Baginska","year":"2013","unstructured":"Baginska J, Viry E, Paggetti J, Medves S, Berchem G, Moussay E, et al. The critical role of the tumor microenvironment in shaping natural killer cell-mediated anti-tumor immunity. Front Immunol. 2013;4:490.","journal-title":"Front Immunol"},{"key":"2632_CR97","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3389\/fimmu.2020.00275","volume":"11","author":"A Ben-Shmuel","year":"2020","unstructured":"Ben-Shmuel A, Biber G, Barda-Saad M. Unleashing natural killer cells in the tumor microenvironment\u2013the next generation of immunotherapy? Front Immunol. 2020;11:275.","journal-title":"Front Immunol"},{"issue":"5","key":"2632_CR98","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/cmi.2015.42","volume":"13","author":"T Krneta","year":"2016","unstructured":"Krneta T, Gillgrass A, Chew M, Ashkar AA. The breast tumor microenvironment alters the phenotype and function of natural killer cells. Cell Mol Immunol. 2016;13(5):628\u201339.","journal-title":"Cell Mol Immunol"},{"issue":"16","key":"2632_CR99","doi-asserted-by":"publisher","first-page":"4037","DOI":"10.3390\/cancers13164037","volume":"13","author":"P Ahluwalia","year":"2021","unstructured":"Ahluwalia P, Ahluwalia M, Mondal AK, Sahajpal NS, Kota V, Rojiani MV, et al. Natural killer cells and dendritic cells: expanding clinical relevance in the non-small cell lung cancer (NSCLC) tumor microenvironment. Cancers. 2021;13(16):4037.","journal-title":"Cancers"},{"issue":"1","key":"2632_CR100","doi-asserted-by":"publisher","first-page":"68","DOI":"10.2174\/156652413804486269","volume":"13","author":"T Krneta","year":"2013","unstructured":"Krneta T, Gillgrass A, A Ashkar A. The influence of macrophages and the tumor microenvironment on natural killer cells. Curr Mol Med. 2013;13(1):68\u201379.","journal-title":"Curr Mol Med"},{"key":"2632_CR101","doi-asserted-by":"publisher","first-page":"633205","DOI":"10.3389\/fimmu.2021.633205","volume":"12","author":"C Zalfa","year":"2021","unstructured":"Zalfa C, Paust S. Natural killer cell interactions with myeloid derived suppressor cells in the tumor microenvironment and implications for cancer immunotherapy. Front Immunol. 2021;12:633205.","journal-title":"Front Immunol"},{"key":"2632_CR102","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3389\/fonc.2019.00051","volume":"9","author":"G Nayyar","year":"2019","unstructured":"Nayyar G, Chu Y, Cairo MS. Overcoming resistance to natural killer cell based immunotherapies for solid tumors. Front Oncol. 2019;9:51.","journal-title":"Front Oncol"},{"key":"2632_CR103","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3389\/fimmu.2015.00202","volume":"6","author":"A Gras Navarro","year":"2015","unstructured":"Gras Navarro A, Bj\u00f6rklund AT, Chekenya M. Therapeutic potential and challenges of natural killer cells in treatment of solid tumors. Front Immunol. 2015;6:202.","journal-title":"Front Immunol"},{"issue":"10","key":"2632_CR104","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.3390\/cancers11101534","volume":"11","author":"S Oh","year":"2019","unstructured":"Oh S, Lee J-H, Kwack K, Choi S-W. Natural killer cell therapy: a new treatment paradigm for solid tumors. Cancers. 2019;11(10):1534.","journal-title":"Cancers"},{"issue":"45","key":"2632_CR105","doi-asserted-by":"publisher","first-page":"2103463","DOI":"10.1002\/smll.202103463","volume":"17","author":"L Gong","year":"2021","unstructured":"Gong L, Li Y, Cui K, Chen Y, Hong H, Li J, et al. Nanobody-engineered natural killer cell conjugates for solid tumor adoptive immunotherapy. Small. 2021;17(45):2103463.","journal-title":"Small"},{"issue":"42","key":"2632_CR106","doi-asserted-by":"publisher","first-page":"1902636","DOI":"10.1002\/smll.201902636","volume":"15","author":"D Zhang","year":"2019","unstructured":"Zhang D, Zheng Y, Lin Z, Lan S, Zhang X, Zheng A, et al. Artificial engineered natural killer cells combined with antiheat endurance as a powerful strategy for enhancing Photothermal-Immunotherapy efficiency of solid tumors. Small. 2019;15(42):1902636.","journal-title":"Small"},{"issue":"1","key":"2632_CR107","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s40164-023-00431-0","volume":"12","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Zhou W, Yang J, Yang J, Wang W. Chimeric antigen receptor engineered natural killer cells for cancer therapy. Experimental Hematol Oncol. 2023;12(1):70.","journal-title":"Experimental Hematol Oncol"},{"issue":"7","key":"2632_CR108","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.3390\/cancers11071040","volume":"11","author":"Z Chen","year":"2019","unstructured":"Chen Z, Yang Y, Liu LL, Lundqvist A. Strategies to augment natural killer (NK) cell activity against solid tumors. Cancers. 2019;11(7):1040.","journal-title":"Cancers"},{"issue":"5","key":"2632_CR109","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41423-019-0224-2","volume":"16","author":"G Habif","year":"2019","unstructured":"Habif G, Crinier A, Andr\u00e9 P, Vivier E, Narni-Mancinelli E. Targeting natural killer cells in solid tumors. Cell Mol Immunol. 2019;16(5):415\u201322.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"2632_CR110","first-page":"4054815","volume":"2018","author":"S Matosevic","year":"2018","unstructured":"Matosevic S. Viral and nonviral engineering of natural killer cells as emerging adoptive cancer immunotherapies. J Immunol Res. 2018;2018(1):4054815.","journal-title":"J Immunol Res"},{"key":"2632_CR111","doi-asserted-by":"publisher","first-page":"1454427","DOI":"10.3389\/fimmu.2024.1454427","volume":"15","author":"H Park","year":"2024","unstructured":"Park H, Kim G, Kim N, Ha S, Yim H. Efficacy and safety of natural killer cell therapy in patients with solid tumors: a systematic review and meta-analysis. Front Immunol. 2024;15:1454427.","journal-title":"Front Immunol"},{"issue":"24","key":"2632_CR112","doi-asserted-by":"publisher","first-page":"2306738","DOI":"10.1002\/smll.202306738","volume":"20","author":"S Kim","year":"2024","unstructured":"Kim S, Li S, Jangid AK, Park HW, Lee DJ, Jung HS, et al. Surface engineering of natural killer cells with CD44-targeting ligands for augmented cancer immunotherapy. Small. 2024;20(24):2306738.","journal-title":"Small"},{"issue":"4","key":"2632_CR113","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s13402-020-00523-7","volume":"43","author":"J Wang","year":"2020","unstructured":"Wang J, Matosevic S. Functional and metabolic targeting of natural killer cells to solid tumors. Cell Oncol. 2020;43(4):577\u2013600.","journal-title":"Cell Oncol"},{"key":"2632_CR114","doi-asserted-by":"publisher","first-page":"607131","DOI":"10.3389\/fimmu.2020.607131","volume":"11","author":"S Mantesso","year":"2020","unstructured":"Mantesso S, Geerts D, Spanholtz J, Ku\u010derov\u00e1 L. Genetic engineering of natural killer cells for enhanced antitumor function. Front Immunol. 2020;11:607131.","journal-title":"Front Immunol"},{"issue":"9","key":"2632_CR115","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41417-021-00336-2","volume":"28","author":"R El-Mayta","year":"2021","unstructured":"El-Mayta R, Zhang Z, Hamilton AG, Mitchell MJ. Delivery technologies to engineer natural killer cells for cancer immunotherapy. Cancer Gene Ther. 2021;28(9):947\u201359.","journal-title":"Cancer Gene Ther"},{"issue":"12","key":"2632_CR116","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1016\/j.ymthe.2017.08.010","volume":"25","author":"EL Siegler","year":"2017","unstructured":"Siegler EL, Kim YJ, Chen X, Siriwon N, Mac J, Rohrs JA, et al. Combination cancer therapy using chimeric antigen receptor-engineered natural killer cells as drug carriers. Mol Ther. 2017;25(12):2607\u201319.","journal-title":"Mol Ther"},{"key":"2632_CR117","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.coi.2018.03.013","volume":"51","author":"M Daher","year":"2018","unstructured":"Daher M, Rezvani K. Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering. Curr Opin Immunol. 2018;51:146\u201353.","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"2632_CR118","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s40425-018-0441-8","volume":"6","author":"J Wang","year":"2018","unstructured":"Wang J, Lupo KB, Chambers AM, Matosevic S. Purinergic targeting enhances immunotherapy of CD73(+) solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells. J Immunother Cancer. 2018;6(1):136.","journal-title":"J Immunother Cancer"},{"issue":"9","key":"2632_CR119","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41423-021-00732-6","volume":"18","author":"C Zhang","year":"2021","unstructured":"Zhang C, Hu Y, Xiao W, Tian Z. Chimeric antigen receptor-and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy. Cell Mol Immunol. 2021;18(9):2083\u2013100.","journal-title":"Cell Mol Immunol"},{"key":"2632_CR120","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3389\/fimmu.2020.00060","volume":"11","author":"C Zhang","year":"2020","unstructured":"Zhang C, Hu Y, Shi C. Targeting natural killer cells for tumor immunotherapy. Front Immunol. 2020;11:60.","journal-title":"Front Immunol"},{"issue":"1","key":"2632_CR121","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13045-020-00998-9","volume":"13","author":"A Yilmaz","year":"2020","unstructured":"Yilmaz A, Cui H, Caligiuri MA, Yu J. Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy. J Hematol Oncol. 2020;13(1):168.","journal-title":"J Hematol Oncol"},{"issue":"7","key":"2632_CR122","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.tibtech.2023.02.003","volume":"41","author":"D Xue","year":"2023","unstructured":"Xue D, Lu S, Zhang H, Zhang L, Dai Z, Kaufman DS, et al. Induced pluripotent stem cell-derived engineered T cells, natural killer cells, macrophages, and dendritic cells in immunotherapy. Trends Biotechnol. 2023;41(7):907\u201322.","journal-title":"Trends Biotechnol"},{"issue":"1","key":"2632_CR123","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s13287-020-01741-4","volume":"11","author":"K Shankar","year":"2020","unstructured":"Shankar K, Capitini CM, Saha K. Genome engineering of induced pluripotent stem cells to manufacture natural killer cell therapies. Stem Cell Res Ther. 2020;11(1):234.","journal-title":"Stem Cell Res Ther"},{"issue":"2","key":"2632_CR124","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.trecan.2022.10.009","volume":"9","author":"JK Wong","year":"2023","unstructured":"Wong JK, Dolcetti R, Rhee H, Simpson F, Souza-Fonseca-Guimaraes F. Weaponizing natural killer cells for solid cancer immunotherapy. Trends Cancer. 2023;9(2):111\u201321.","journal-title":"Trends Cancer"},{"issue":"6","key":"2632_CR125","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/j.1399-0039.2011.01796.x","volume":"78","author":"DR Shook","year":"2011","unstructured":"Shook DR, Campana D. Natural killer cell engineering for cellular therapy of cancer. Tissue Antigens. 2011;78(6):409\u201315.","journal-title":"Tissue Antigens"},{"issue":"12","key":"2632_CR126","doi-asserted-by":"publisher","first-page":"3871","DOI":"10.3390\/cancers12123871","volume":"12","author":"I Navin","year":"2020","unstructured":"Navin I, Lam MT, Parihar R. Design and implementation of NK cell-based immunotherapy to overcome the solid tumor microenvironment. Cancers. 2020;12(12):3871.","journal-title":"Cancers"},{"key":"2632_CR127","doi-asserted-by":"publisher","first-page":"e73699","DOI":"10.7554\/eLife.73699","volume":"11","author":"AM Chambers","year":"2022","unstructured":"Chambers AM, Lupo KB, Wang J, Cao J, Utturkar S, Lanman N, et al. Engineered natural killer cells impede the immunometabolic CD73-adenosine axis in solid tumors. Elife. 2022;11:e73699.","journal-title":"Elife"},{"issue":"2","key":"2632_CR128","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/cac2.12394","volume":"43","author":"F Ghaedrahmati","year":"2023","unstructured":"Ghaedrahmati F, Esmaeil N, Abbaspour M. Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors. Cancer Commun. 2023;43(2):177\u2013213.","journal-title":"Cancer Commun"},{"issue":"7","key":"2632_CR129","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1021\/acsbiomaterials.0c00259","volume":"6","author":"MN Temples","year":"2020","unstructured":"Temples MN, Adjei IM, Nimocks PM, Djeu J, Sharma B. Engineered three-dimensional tumor models to study natural killer cell suppression. ACS Biomaterials Sci Eng. 2020;6(7):4179\u201399.","journal-title":"ACS Biomaterials Sci Eng"},{"issue":"4","key":"2632_CR130","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3892\/etm.2021.9771","volume":"21","author":"X Peng","year":"2021","unstructured":"Peng X, Chen L, Chen L, Wang B, Wang Y, Zhan X. Chimeric antigen receptor-natural killer cells: novel insight into immunotherapy for solid tumors. Experimental Therapeutic Med. 2021;21(4):340.","journal-title":"Experimental Therapeutic Med"},{"issue":"1","key":"2632_CR131","doi-asserted-by":"publisher","first-page":"1294368","DOI":"10.1080\/20013078.2017.1294368","volume":"6","author":"AY Jong","year":"2017","unstructured":"Jong AY, Wu C-H, Li J, Sun J, Fabbri M, Wayne AS, et al. Large-scale isolation and cytotoxicity of extracellular vesicles derived from activated human natural killer cells. J Extracell Vesicles. 2017;6(1):1294368.","journal-title":"J Extracell Vesicles"},{"issue":"1","key":"2632_CR132","doi-asserted-by":"publisher","first-page":"1588538","DOI":"10.1080\/20013078.2019.1588538","volume":"8","author":"C-H Wu","year":"2019","unstructured":"Wu C-H, Li J, Li L, Sun J, Fabbri M, Wayne AS, et al. Extracellular vesicles derived from natural killer cells use multiple cytotoxic proteins and killing mechanisms to target cancer cells. J Extracell Vesicles. 2019;8(1):1588538.","journal-title":"J Extracell Vesicles"},{"key":"2632_CR133","doi-asserted-by":"publisher","first-page":"658698","DOI":"10.3389\/fimmu.2021.658698","volume":"12","author":"F Wu","year":"2021","unstructured":"Wu F, Xie M, Hun M, She Z, Li C, Luo S, et al. Natural killer cell-derived extracellular vesicles: novel players in cancer immunotherapy. Front Immunol. 2021;12:658698.","journal-title":"Front Immunol"},{"issue":"6","key":"2632_CR134","doi-asserted-by":"publisher","first-page":"874","DOI":"10.3390\/cancers11060874","volume":"11","author":"J Zhao","year":"2019","unstructured":"Zhao J, Schl\u00f6\u00dfer HA, Wang Z, Qin J, Li J, Popp F, et al. Tumor-derived extracellular vesicles inhibit natural killer cell function in pancreatic cancer. Cancers. 2019;11(6):874.","journal-title":"Cancers"},{"key":"2632_CR135","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.biomaterials.2018.10.034","volume":"190","author":"L Zhu","year":"2019","unstructured":"Zhu L, Kalimuthu S, Oh JM, Gangadaran P, Baek SH, Jeong SY, et al. Enhancement of antitumor potency of extracellular vesicles derived from natural killer cells by IL-15 priming. Biomaterials. 2019;190:38\u201350.","journal-title":"Biomaterials"},{"issue":"4","key":"2632_CR136","doi-asserted-by":"publisher","first-page":"4026","DOI":"10.3390\/ijms24044026","volume":"24","author":"AML Chan","year":"2023","unstructured":"Chan AML, Cheah JM, Lokanathan Y, Ng MH, Law JX. Natural killer cell-derived extracellular vesicles as a promising immunotherapeutic strategy for cancer: a systematic review. Int J Mol Sci. 2023;24(4):4026.","journal-title":"Int J Mol Sci"},{"key":"2632_CR137","doi-asserted-by":"publisher","first-page":"1122585","DOI":"10.3389\/fbioe.2023.1122585","volume":"11","author":"Y Qi","year":"2023","unstructured":"Qi Y, Zhao X, Dong Y, Wang M, Wang J, Fan Z, et al. Opportunities and challenges of natural killer cell-derived extracellular vesicles. Front Bioeng Biotechnol. 2023;11:1122585.","journal-title":"Front Bioeng Biotechnol"},{"issue":"6","key":"2632_CR138","doi-asserted-by":"publisher","first-page":"e12075","DOI":"10.1002\/jev2.12075","volume":"10","author":"F Del Vecchio","year":"2021","unstructured":"Del Vecchio F, Martinez-Rodriguez V, Schukking M, Cocks A, Broseghini E, Fabbri M. Professional killers: the role of extracellular vesicles in the reciprocal interactions between natural killer, CD8\u2009+\u2009cytotoxic T\u2010cells and tumour cells. J Extracell Vesicles. 2021;10(6):e12075.","journal-title":"J Extracell Vesicles"},{"key":"2632_CR139","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3389\/fimmu.2020.00262","volume":"11","author":"C Federici","year":"2020","unstructured":"Federici C, Shahaj E, Cecchetti S, Camerini S, Casella M, Iessi E, et al. Natural-killer-derived extracellular vesicles: immune sensors and interactors. Front Immunol. 2020;11:262.","journal-title":"Front Immunol"},{"issue":"4","key":"2632_CR140","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3390\/cancers11040461","volume":"11","author":"B Bassani","year":"2019","unstructured":"Bassani B, Baci D, Gallazzi M, Poggi A, Bruno A, Mortara L. Natural killer cells as key players of tumor progression and angiogenesis: old and novel tools to divert their pro-tumor activities into potent anti-tumor effects. Cancers. 2019;11(4):461.","journal-title":"Cancers"},{"issue":"18","key":"2632_CR141","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1158\/0008-5472.CAN-18-3962","volume":"79","author":"DC Hinshaw","year":"2019","unstructured":"Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. Cancer Res. 2019;79(18):4557\u201366.","journal-title":"Cancer Res"},{"key":"2632_CR142","doi-asserted-by":"crossref","unstructured":"Noh J-Y, Jung H. Natural killer cells and immunotherapy. MDPI; 2023. p. 8760.","DOI":"10.3390\/ijms24108760"},{"key":"2632_CR143","doi-asserted-by":"publisher","first-page":"1135148","DOI":"10.3389\/fimmu.2023.1135148","volume":"14","author":"V Carannante","year":"2023","unstructured":"Carannante V, Wiklund M, \u00d6nfelt B. In vitro models to study natural killer cell dynamics in the tumor microenvironment. Front Immunol. 2023;14:1135148.","journal-title":"Front Immunol"},{"key":"2632_CR144","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3389\/fimmu.2019.00128","volume":"10","author":"M Martinez","year":"2019","unstructured":"Martinez M, Moon EK. CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment. Front Immunol. 2019;10:128.","journal-title":"Front Immunol"},{"key":"2632_CR145","doi-asserted-by":"publisher","first-page":"683","DOI":"10.3389\/fimmu.2017.00683","volume":"8","author":"M Messaoudene","year":"2017","unstructured":"Messaoudene M, Frazao A, Gavlovsky PJ, Toubert A, Dulphy N, Caignard A. Patient\u2019s natural killer cells in the era of targeted therapies: role for tumor killers. Front Immunol. 2017;8:683.","journal-title":"Front Immunol"},{"issue":"10","key":"2632_CR146","doi-asserted-by":"publisher","first-page":"e003050","DOI":"10.1136\/jitc-2021-003050","volume":"9","author":"C-I Jan","year":"2021","unstructured":"Jan C-I, Huang S-W, Canoll P, Bruce JN, Lin Y-C, Pan C-M, et al. Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors. J Immunother Cancer. 2021;9(10):e003050.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"2632_CR147","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1158\/2159-8290.CD-13-0985","volume":"4","author":"I Melero","year":"2014","unstructured":"Melero I, Rouzaut A, Motz GT, Coukos G. T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy. Cancer Discov. 2014;4(5):522\u20136.","journal-title":"Cancer Discov"},{"issue":"10","key":"2632_CR148","doi-asserted-by":"publisher","first-page":"6917","DOI":"10.1007\/s00432-023-04650-0","volume":"149","author":"AC dos Santos Cunha","year":"2023","unstructured":"dos Santos Cunha AC, Simon AG, Zander T, Buettner R, Bruns CJ, Schroeder W, et al. Dissecting the inflammatory tumor microenvironment of esophageal adenocarcinoma: mast cells and natural killer cells are favorable prognostic factors and associated with less extensive disease. J Cancer Res Clin Oncol. 2023;149(10):6917\u201329.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"2632_CR149","doi-asserted-by":"publisher","first-page":"8459496","DOI":"10.1155\/2020\/8459496","volume":"2020","author":"C Yang","year":"2020","unstructured":"Yang C, Li Y, Yang Y, Chen Z. Overview of strategies to improve therapy against tumors using natural killer cell. J Immunol Res. 2020;2020(1):8459496.","journal-title":"J Immunol Res"},{"issue":"1","key":"2632_CR150","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12943-020-01238-x","volume":"19","author":"S-Y Wu","year":"2020","unstructured":"Wu S-Y, Fu T, Jiang Y-Z, Shao Z-M. Natural killer cells in cancer biology and therapy. Mol Cancer. 2020;19(1):120.","journal-title":"Mol Cancer"},{"key":"2632_CR151","unstructured":"Chambers A. Immunotherapy of solid tumors with Immunometabolically-Retargeted natural killer cells. Purdue University; 2021."},{"key":"2632_CR152","doi-asserted-by":"publisher","DOI":"10.1615\/critrevimmunol.v30.i6.30","author":"Salem Chouaib","year":"2010","unstructured":"Chouaib S, Kieda C, Benlalam H, Noman MZ, Mami-Chouaib F, Ruegg C. Endothelial cells as key determinants of the tumor microenvironment: interaction with tumor cells, extracellular matrix and immune killer cells. Crit Reviews\u2122 Immunol. 2010;30(6):529-545. https:\/\/doi.org\/10.1615\/critrevimmunol.v30.i6.30","journal-title":"Critical Reviews\u2122 in Immunology"},{"issue":"2","key":"2632_CR153","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s12307-012-0125-8","volume":"6","author":"A Stojanovic","year":"2013","unstructured":"Stojanovic A, Correia MP, Cerwenka A. Shaping of NK cell responses by the tumor microenvironment. Cancer Microenvironment. 2013;6(2):135\u201346.","journal-title":"Cancer Microenvironment"},{"key":"2632_CR154","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.canlet.2021.07.032","volume":"520","author":"H Raskov","year":"2021","unstructured":"Raskov H, Orhan A, Salanti A, Gaggar S, G\u00f6genur I. Natural killer cells in cancer and cancer immunotherapy. Cancer Lett. 2021;520:233\u201342.","journal-title":"Cancer Lett"},{"issue":"24","key":"2632_CR155","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1101\/gad.169029.111","volume":"25","author":"SL Shiao","year":"2011","unstructured":"Shiao SL, Ganesan AP, Rugo HS, Coussens LM. Immune microenvironments in solid tumors: new targets for therapy. Genes Dev. 2011;25(24):2559\u201372.","journal-title":"Genes Dev"},{"issue":"4","key":"2632_CR156","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1158\/0008-5472.CAN-17-2826","volume":"78","author":"A Young","year":"2018","unstructured":"Young A, Ngiow SF, Gao Y, Patch A-M, Barkauskas DS, Messaoudene M, et al. A2AR adenosine signaling suppresses natural killer cell maturation in the tumor microenvironment. Cancer Res. 2018;78(4):1003\u201316.","journal-title":"Cancer Res"},{"issue":"1","key":"2632_CR157","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s12935-023-03134-y","volume":"23","author":"A Rahimi","year":"2023","unstructured":"Rahimi A, Malakoutikhah Z, Rahimmanesh I, Ferns GA, Nedaeinia R, Ishaghi SMM, et al. The nexus of natural killer cells and melanoma tumor microenvironment: crosstalk, chemotherapeutic potential, and innovative NK cell-based therapeutic strategies. Cancer Cell Int. 2023;23(1):312.","journal-title":"Cancer Cell Int"},{"key":"2632_CR158","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.canlet.2021.04.021","volume":"511","author":"G Wei","year":"2021","unstructured":"Wei G, Zhang H, Zhao H, Wang J, Wu N, Li L, et al. Emerging immune checkpoints in the tumor microenvironment: implications for cancer immunotherapy. Cancer Lett. 2021;511:68\u201376.","journal-title":"Cancer Lett"},{"issue":"5","key":"2632_CR159","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.molmed.2019.02.003","volume":"25","author":"RE Veerman","year":"2019","unstructured":"Veerman RE, Akpinar GG, Eldh M, Gabrielsson S. Immune cell-derived extracellular vesicles\u2013functions and therapeutic applications. Trends Mol Med. 2019;25(5):382\u201394.","journal-title":"Trends Mol Med"},{"key":"2632_CR160","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.virol.2015.07.008","volume":"485","author":"ET Chivero","year":"2015","unstructured":"Chivero ET, Bhattarai N, McLinden JH, Xiang J, Stapleton JT. Human pegivirus (HPgV; formerly known as GBV-C) inhibits IL-12 dependent natural killer cell function. Virology. 2015;485:116\u201327.","journal-title":"Virology"},{"issue":"4","key":"2632_CR161","first-page":"633","volume":"22","author":"A Korenevsky","year":"2020","unstructured":"Korenevsky A, Shcherbitskaia A, Berezkina M, Markova K, Alexandrova E, Balabas O, et al. MALDI-TOF mass spectrometric protein profiling of microvesicles produced by the NK-92 natural killer cell line. \u041c\u0435\u0434\u0438\u0446\u0438\u043d\u0441\u043a\u0430\u044f \u0438\u043c\u043c\u0443\u043d\u043e\u043b\u043e\u0433\u0438\u044f. 2020;22(4):633\u201346.","journal-title":"\u041c\u0435\u0434\u0438\u0446\u0438\u043d\u0441\u043a\u0430\u044f \u0438\u043c\u043c\u0443\u043d\u043e\u043b\u043e\u0433\u0438\u044f"},{"issue":"4","key":"2632_CR162","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41577-021-00574-3","volume":"22","author":"M Philip","year":"2022","unstructured":"Philip M, Schietinger A. CD8\u2009+\u2009T cell differentiation and dysfunction in cancer. Nat Rev Immunol. 2022;22(4):209\u201323.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"2632_CR163","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s12307-012-0127-6","volume":"6","author":"S Hadrup","year":"2013","unstructured":"Hadrup S, Donia M, Thor Straten P. Effector CD4 and CD8 T cells and their role in the tumor microenvironment. Cancer Microenvironment. 2013;6(2):123\u201333.","journal-title":"Cancer Microenvironment"},{"issue":"22","key":"2632_CR164","doi-asserted-by":"publisher","first-page":"3626","DOI":"10.3390\/cells11223626","volume":"11","author":"A Cheever","year":"2022","unstructured":"Cheever A, Townsend M, O\u2019Neill K. Tumor microenvironment immunosuppression: a roadblock to CAR T-cell advancement in solid tumors. Cells. 2022;11(22):3626.","journal-title":"Cells"},{"issue":"1","key":"2632_CR165","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/j.1600-065X.2006.00442.x","volume":"213","author":"TF Gajewski","year":"2006","unstructured":"Gajewski TF, Meng Y, Blank C, Brown I, Kacha A, Kline J, et al. Immune resistance orchestrated by the tumor microenvironment. Immunol Rev. 2006;213(1):131\u201345.","journal-title":"Immunol Rev"},{"issue":"1","key":"2632_CR166","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s42255-020-00317-z","volume":"3","author":"I Elia","year":"2021","unstructured":"Elia I, Haigis MC. Metabolites and the tumour microenvironment: from cellular mechanisms to systemic metabolism. Nat Metabolism. 2021;3(1):21\u201332.","journal-title":"Nat Metabolism"},{"issue":"7","key":"2632_CR167","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.3390\/cancers12071760","volume":"12","author":"AM Cornel","year":"2020","unstructured":"Cornel AM, Mimpen IL, Nierkens S. MHC class I downregulation in cancer: underlying mechanisms and potential targets for cancer immunotherapy. Cancers. 2020;12(7):1760.","journal-title":"Cancers"},{"issue":"7637","key":"2632_CR168","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I. Elements of cancer immunity and the cancer\u2013immune set point. Nature. 2017;541(7637):321\u201330.","journal-title":"Nature"},{"issue":"11","key":"2632_CR169","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20(11):651\u201368.","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"2632_CR170","doi-asserted-by":"publisher","first-page":"e002723","DOI":"10.1136\/jitc-2021-002723","volume":"9","author":"K Kirtane","year":"2021","unstructured":"Kirtane K, Elmariah H, Chung CH, Abate-Daga D. Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead. J Immunother Cancer. 2021;9(7):e002723.","journal-title":"J Immunother Cancer"},{"issue":"10","key":"2632_CR171","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1158\/1078-0432.CCR-22-1922","volume":"29","author":"A Betof Warner","year":"2023","unstructured":"Betof Warner A, Corrie PG, Hamid O. Tumor-infiltrating lymphocyte therapy in melanoma: facts to the future. Clin Cancer Res. 2023;29(10):1835\u201354.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2632_CR172","doi-asserted-by":"publisher","first-page":"e1174","DOI":"10.1002\/ctm2.1174","volume":"13","author":"M Arnaud","year":"2023","unstructured":"Arnaud M, Coukos G, Harari A. Towards next-generation TIL therapy: TILs enriched in neoepitope\u2010specific T cells. Clin Translational Med. 2023;13(1):e1174.","journal-title":"Clin Translational Med"},{"issue":"1","key":"2632_CR173","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12916-021-02006-4","volume":"19","author":"S Wang","year":"2021","unstructured":"Wang S, Sun J, Chen K, Ma P, Lei Q, Xing S, et al. Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors. BMC Med. 2021;19(1):140.","journal-title":"BMC Med"},{"issue":"24","key":"2632_CR174","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1200\/JCO.21.00612","volume":"39","author":"AA Sarnaik","year":"2021","unstructured":"Sarnaik AA, Hamid O, Khushalani NI, Lewis KD, Medina T, Kluger HM, et al. Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma. J Clin Oncol. 2021;39(24):2656\u201366.","journal-title":"J Clin Oncol"},{"key":"2632_CR175","doi-asserted-by":"crossref","unstructured":"Jazaeri AA, Zsiros E, Amaria RN, Artz AS, Edwards RP, Wenham RM, et al. Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma. American Society of Clinical Oncology; 2019.","DOI":"10.1016\/j.ygyno.2018.04.274"},{"issue":"3","key":"2632_CR176","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.jcyt.2021.08.004","volume":"24","author":"J Chu","year":"2022","unstructured":"Chu J, Wang C, Ma Q, Dai H, Xu J, Ogunnaike EA, et al. Coupling programmed cell death 1-positive tumor-infiltrating t cells with anti-programmed cell death 1 antibody improves the efficacy of adoptive T-cell therapy. Cytotherapy. 2022;24(3):291\u2013301.","journal-title":"Cytotherapy"},{"issue":"11","key":"2632_CR177","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1038\/s41416-021-01353-6","volume":"124","author":"M Morotti","year":"2021","unstructured":"Morotti M, Albukhari A, Alsaadi A, Artibani M, Brenton JD, Curbishley SM, et al. Promises and challenges of adoptive T-cell therapies for solid tumours. Br J Cancer. 2021;124(11):1759\u201376.","journal-title":"Br J Cancer"},{"key":"2632_CR178","doi-asserted-by":"publisher","first-page":"738456","DOI":"10.3389\/fimmu.2021.738456","volume":"12","author":"N Ghahri-Saremi","year":"2021","unstructured":"Ghahri-Saremi N, Akbari B, Soltantoyeh T, Hadjati J, Ghassemi S, Mirzaei HR. Genetic modification of cytokine signaling to enhance efficacy of CAR T cell therapy in solid tumors. Front Immunol. 2021;12:738456.","journal-title":"Front Immunol"},{"key":"2632_CR179","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.3389\/fimmu.2019.02250","volume":"10","author":"L Zhao","year":"2019","unstructured":"Zhao L, Cao YJ. Engineered T cell therapy for cancer in the clinic. Front Immunol. 2019;10:2250.","journal-title":"Front Immunol"},{"issue":"7","key":"2632_CR180","doi-asserted-by":"publisher","first-page":"eadf3700","DOI":"10.1126\/sciadv.adf3700","volume":"9","author":"E Baulu","year":"2023","unstructured":"Baulu E, Gardet C, Chuvin N, Depil S. TCR-engineered T cell therapy in solid tumors: state of the Art and perspectives. Sci Adv. 2023;9(7):eadf3700.","journal-title":"Sci Adv"},{"issue":"1","key":"2632_CR181","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/cpt.1674","volume":"107","author":"SA Holstein","year":"2020","unstructured":"Holstein SA, Lunning MA. CAR T-cell therapy in hematologic malignancies: a voyage in progress. Clin Pharmacol Ther. 2020;107(1):112\u201322.","journal-title":"Clin Pharmacol Ther"},{"issue":"6382","key":"2632_CR182","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June CH, O\u2019Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361\u20135.","journal-title":"Science"},{"key":"2632_CR183","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/jha2.356","volume":"3","author":"U Patel","year":"2022","unstructured":"Patel U, Abernathy J, Savani BN, Oluwole O, Sengsayadeth S, Dholaria B. CAR T cell therapy in solid tumors: A review of current clinical trials. EJHaem. 2022;3:24\u201331.","journal-title":"EJHaem"},{"issue":"4","key":"2632_CR184","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1158\/1078-0432.CCR-18-2035","volume":"25","author":"MC O\u2019Leary","year":"2019","unstructured":"O\u2019Leary MC, Lu X, Huang Y, Lin X, Mahmood I, Przepiorka D, et al. FDA approval summary: tisagenlecleucel for treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Clin Cancer Res. 2019;25(4):1142\u20136.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2632_CR185","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s11912-023-01380-x","volume":"25","author":"G Guzman","year":"2023","unstructured":"Guzman G, Reed MR, Bielamowicz K, Koss B, Rodriguez A. CAR-T therapies in solid tumors: opportunities and challenges. Curr Oncol Rep. 2023;25(5):479\u201389.","journal-title":"Curr Oncol Rep"},{"issue":"5","key":"2632_CR186","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.3390\/cancers15051414","volume":"15","author":"AS Luksik","year":"2023","unstructured":"Luksik AS, Yazigi E, Shah P, Jackson CM. CAR T cell therapy in glioblastoma: overcoming challenges related to antigen expression. Cancers. 2023;15(5):1414.","journal-title":"Cancers"},{"issue":"4","key":"2632_CR187","doi-asserted-by":"publisher","first-page":"93","DOI":"10.46989\/001c.124277","volume":"6","author":"ST Bhaskar","year":"2024","unstructured":"Bhaskar ST, Dholaria B, Savani BN, Sengsayadeth S, Oluwole O. Overview of approved CAR-T products and utility in clinical practice. Clin Hematol Int. 2024;6(4):93.","journal-title":"Clin Hematol Int"},{"key":"2632_CR188","doi-asserted-by":"publisher","first-page":"1034257","DOI":"10.3389\/fcell.2022.1034257","volume":"10","author":"X Zhu","year":"2022","unstructured":"Zhu X, Li Q, Zhu X. Mechanisms of CAR T cell exhaustion and current counteraction strategies. Front Cell Dev Biology. 2022;10:1034257.","journal-title":"Front Cell Dev Biology"},{"key":"2632_CR189","doi-asserted-by":"publisher","first-page":"817296","DOI":"10.3389\/fimmu.2022.817296","volume":"13","author":"Y-J Lin","year":"2022","unstructured":"Lin Y-J, Mashouf LA, Lim M. CAR T cell therapy in primary brain tumors: current investigations and the future. Front Immunol. 2022;13:817296.","journal-title":"Front Immunol"},{"issue":"5","key":"2632_CR190","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","volume":"36","author":"R Grosser","year":"2019","unstructured":"Grosser R, Cherkassky L, Chintala N, Adusumilli PS. Combination immunotherapy with CAR T cells and checkpoint Blockade for the treatment of solid tumors. Cancer Cell. 2019;36(5):471\u201382.","journal-title":"Cancer Cell"},{"key":"2632_CR191","doi-asserted-by":"publisher","first-page":"1045024","DOI":"10.3389\/fimmu.2023.1045024","volume":"14","author":"K Zhang","year":"2023","unstructured":"Zhang K, Chen H, Li F, Huang S, Chen F, Li Y. Bright future or blind alley? CAR-T cell therapy for solid tumors. Front Immunol. 2023;14:1045024.","journal-title":"Front Immunol"},{"issue":"5","key":"2632_CR192","doi-asserted-by":"publisher","first-page":"790","DOI":"10.3390\/cells11050790","volume":"11","author":"V Calvo","year":"2022","unstructured":"Calvo V, Izquierdo M. T lymphocyte and CAR-T cell-derived extracellular vesicles and their applications in cancer therapy. Cells. 2022;11(5):790.","journal-title":"Cells"},{"issue":"4","key":"2632_CR193","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.3390\/cancers15041052","volume":"15","author":"S Pagotto","year":"2023","unstructured":"Pagotto S, Simeone P, Brocco D, Catitti G, De Bellis D, Vespa S, et al. CAR-T-derived extracellular vesicles: a promising development of CAR-T anti-tumor therapy. Cancers. 2023;15(4):1052.","journal-title":"Cancers"},{"issue":"1","key":"2632_CR194","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s13287-024-03783-4","volume":"15","author":"F Sani","year":"2024","unstructured":"Sani F, Shojaei S, Tabatabaei SA, Khorraminejad-Shirazi M, Latifi M, Sani M, et al. CAR-T cell-derived exosomes: a new perspective for cancer therapy. Stem Cell Res Ther. 2024;15(1):174.","journal-title":"Stem Cell Res Ther"},{"key":"2632_CR195","doi-asserted-by":"publisher","first-page":"107352","DOI":"10.1016\/j.phrs.2024.107352","volume":"208","author":"B Spokeviciute","year":"2024","unstructured":"Spokeviciute B, Kholia S, Brizzi MF. Chimeric antigen receptor (CAR) T-cell therapy: Harnessing extracellular vesicles for enhanced efficacy. Pharmacol Res. 2024;208:107352.","journal-title":"Pharmacol Res"},{"issue":"1","key":"2632_CR196","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s41232-024-00358-x","volume":"44","author":"S-H Zhang","year":"2024","unstructured":"Zhang S-H, Peng L-L, Chen Y-F, Xu Y, Moradi V. Focusing on exosomes to overcome the existing bottlenecks of CAR-T cell therapy. Inflamm Regeneration. 2024;44(1):45.","journal-title":"Inflamm Regeneration"},{"key":"2632_CR197","doi-asserted-by":"publisher","first-page":"881427","DOI":"10.3389\/fimmu.2022.881427","volume":"13","author":"Y Qin","year":"2022","unstructured":"Qin Y, Lu F, Lyu K, Chang AE, Li Q. Emerging concepts regarding pro-and anti tumor properties of B cells in tumor immunity. Front Immunol. 2022;13:881427.","journal-title":"Front Immunol"},{"issue":"8","key":"2632_CR198","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41581-023-00706-z","volume":"19","author":"Y Sato","year":"2023","unstructured":"Sato Y, Silina K, Van Den Broek M, Hirahara K, Yanagita M. The roles of tertiary lymphoid structures in chronic diseases. Nat Rev Nephrol. 2023;19(8):525\u201337.","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"2632_CR199","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","volume":"19","author":"C Saut\u00e8s-Fridman","year":"2019","unstructured":"Saut\u00e8s-Fridman C, Petitprez F, Calderaro J, Fridman WH. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer. 2019;19(6):307\u201325.","journal-title":"Nat Rev Cancer"},{"key":"2632_CR200","doi-asserted-by":"publisher","unstructured":"Catal\u00e1n D, Mansilla M, Ferrier A, Soto L, Oleinika K, Aguill\u00f3n J, et al. Immunosuppressive mechanisms of regulatory B cells. Front Immunol. 2021;12:611795. Epub 2021\/05\/18.2021.611795.PubMed PMID: 33995344; 2021. https:\/\/doi.org\/10.3389\/fimmu .\u00a0","DOI":"10.3389\/fimmu"},{"issue":"1","key":"2632_CR201","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s40425-016-0145-x","volume":"4","author":"M Schwartz","year":"2016","unstructured":"Schwartz M, Zhang Y, Rosenblatt JD. B cell regulation of the anti-tumor response and role in carcinogenesis. J Immunother Cancer. 2016;4(1):40.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"2632_CR202","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.ccell.2023.01.009","volume":"41","author":"EN Arner","year":"2023","unstructured":"Arner EN, Rathmell JC. Metabolic programming and immune suppression in the tumor microenvironment. Cancer Cell. 2023;41(3):421\u201333.","journal-title":"Cancer Cell"},{"issue":"4","key":"2632_CR203","doi-asserted-by":"publisher","first-page":"399","DOI":"10.4103\/0973-1482.91999","volume":"7","author":"I Tazi","year":"2011","unstructured":"Tazi I, Nafil H, Mahmal L. Monoclonal antibodies in hematological malignancies: past, present and future. J Cancer Res Ther. 2011;7(4):399\u2013407.","journal-title":"J Cancer Res Ther"},{"issue":"6","key":"2632_CR204","first-page":"676","volume":"2","author":"P Boross","year":"2012","unstructured":"Boross P, Leusen JH. Mechanisms of action of CD20 antibodies. Am J Cancer Res. 2012;2(6):676.","journal-title":"Am J Cancer Res"},{"issue":"14","key":"2632_CR205","doi-asserted-by":"publisher","first-page":"5009","DOI":"10.3390\/ijms21145009","volume":"21","author":"C Barbari","year":"2020","unstructured":"Barbari C, Fontaine T, Parajuli P, Lamichhane N, Jakubski S, Lamichhane P, et al. Immunotherapies and combination strategies for immuno-oncology. Int J Mol Sci. 2020;21(14):5009.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2632_CR206","doi-asserted-by":"publisher","first-page":"5938","DOI":"10.3390\/ijms24065938","volume":"24","author":"W Shalata","year":"2023","unstructured":"Shalata W, Zolnoorian J, Migliozzi G, Jama AA, Dudnik Y, Cohen AY, et al. Long-lasting therapeutic response following treatment with pembrolizumab in patients with non-small cell lung cancer: a real-world experience. Int J Mol Sci. 2023;24(6):5938.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"2632_CR207","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1080\/13543784.2020.1800638","volume":"29","author":"E Bourbon","year":"2020","unstructured":"Bourbon E, Salles G. Polatuzumab vedotin: an investigational anti-CD79b antibody drug conjugate for the treatment of diffuse large B-cell lymphoma. Expert Opin Investig Drugs. 2020;29(10):1079\u201388.","journal-title":"Expert Opin Investig Drugs"},{"key":"2632_CR208","doi-asserted-by":"publisher","first-page":"1231315","DOI":"10.3389\/fimmu.2023.1231315","volume":"14","author":"L Esparcia-Pinedo","year":"2023","unstructured":"Esparcia-Pinedo L, Romero-Laorden N, Alfranca A. Tertiary lymphoid structures and B lymphocytes: a promising therapeutic strategy to fight cancer. Front Immunol. 2023;14:1231315.","journal-title":"Front Immunol"},{"issue":"11","key":"2632_CR209","doi-asserted-by":"publisher","first-page":"5365","DOI":"10.7150\/thno.58390","volume":"11","author":"Y-T Liu","year":"2021","unstructured":"Liu Y-T, Sun Z-J. Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics. 2021;11(11):5365.","journal-title":"Theranostics"},{"issue":"12","key":"2632_CR210","doi-asserted-by":"publisher","first-page":"5524","DOI":"10.3390\/ijms26125524","volume":"26","author":"A Smolarska","year":"2025","unstructured":"Smolarska A, Kokoszka Z, Naliwajko M, Strupczewska J, Tondera J, Wiater M, et al. Cell-Based therapies for solid tumors: challenges and advances. Int J Mol Sci. 2025;26(12):5524.","journal-title":"Int J Mol Sci"},{"key":"2632_CR211","doi-asserted-by":"publisher","first-page":"1035276","DOI":"10.3389\/fimmu.2022.1035276","volume":"13","author":"J Wei","year":"2022","unstructured":"Wei J, Yang Y, Wang G, Liu M. Current landscape and future directions of bispecific antibodies in cancer immunotherapy. Front Immunol. 2022;13:1035276.","journal-title":"Front Immunol"},{"issue":"24","key":"2632_CR212","doi-asserted-by":"publisher","first-page":"6125","DOI":"10.1158\/1078-0432.CCR-18-1481","volume":"24","author":"MC Wouters","year":"2018","unstructured":"Wouters MC, Nelson BH. Prognostic significance of tumor-infiltrating B cells and plasma cells in human cancer. Clin Cancer Res. 2018;24(24):6125\u201335.","journal-title":"Clin Cancer Res"},{"key":"2632_CR213","doi-asserted-by":"publisher","first-page":"102443","DOI":"10.1016\/j.coi.2024.102443","volume":"88","author":"OP Skinner","year":"2024","unstructured":"Skinner OP, Asad S, Haque A. Advances and challenges in investigating B-cells via single-cell transcriptomics. Curr Opin Immunol. 2024;88:102443.","journal-title":"Curr Opin Immunol"},{"key":"2632_CR214","doi-asserted-by":"publisher","first-page":"566401","DOI":"10.3389\/fphar.2020.566401","volume":"11","author":"Y Shi","year":"2021","unstructured":"Shi Y, Tomczak K, Li J, Ochieng JK, Lee Y, Haymaker C. Next-generation immunotherapies to improve anticancer immunity. Front Pharmacol. 2021;11:566401.","journal-title":"Front Pharmacol"},{"issue":"3","key":"2632_CR215","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3390\/cancers13030404","volume":"13","author":"VM Qin","year":"2021","unstructured":"Qin VM, D\u2019Souza C, Neeson PJ, Zhu JJ. Chimeric antigen receptor beyond CAR-T cells. Cancers. 2021;13(3):404.","journal-title":"Cancers"},{"issue":"6","key":"2632_CR216","doi-asserted-by":"publisher","first-page":"879","DOI":"10.3390\/vaccines10060879","volume":"10","author":"SL Gupta","year":"2022","unstructured":"Gupta SL, Khan N, Basu S, Soni V. B-cell-based immunotherapy: a promising new alternative. Vaccines. 2022;10(6):879.","journal-title":"Vaccines"},{"issue":"14","key":"2632_CR217","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/sj.gt.3302570","volume":"12","author":"P Sinn","year":"2005","unstructured":"Sinn P, Sauter S, McCray P. Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors\u2013design, biosafety, and production. Gene Ther. 2005;12(14):1089\u201398.","journal-title":"Gene Ther"},{"issue":"10","key":"2632_CR218","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1038\/mt.2010.178","volume":"18","author":"C Frecha","year":"2010","unstructured":"Frecha C, L\u00e9vy C, Cosset F-L, Verhoeyen E. Advances in the field of lentivector-based transduction of T and B lymphocytes for gene therapy. Mol Ther. 2010;18(10):1748\u201357.","journal-title":"Mol Ther"},{"key":"2632_CR219","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.addr.2018.09.002","volume":"141","author":"C Hutmacher","year":"2019","unstructured":"Hutmacher C, Neri D. Antibody-cytokine fusion proteins: biopharmaceuticals with Immunomodulatory properties for cancer therapy. Adv Drug Deliv Rev. 2019;141:67\u201391.","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"2632_CR220","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41423-020-0417-8","volume":"17","author":"H Li","year":"2020","unstructured":"Li H, Er Saw P, Song E. Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics. Cell Mol Immunol. 2020;17(5):451\u201361.","journal-title":"Cell Mol Immunol"},{"key":"2632_CR221","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.actbio.2021.02.026","volume":"133","author":"D Stoycheva","year":"2021","unstructured":"Stoycheva D, Simsek H, Weber W, Hauser AE, Klotzsch E. External cues to drive B cell function towards immunotherapy. Acta Biomater. 2021;133:222\u201330.","journal-title":"Acta Biomater"},{"issue":"2","key":"2632_CR222","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.molimm.2014.01.014","volume":"62","author":"EC Rosser","year":"2014","unstructured":"Rosser EC, Blair PA, Mauri C. Cellular targets of regulatory B cell-mediated suppression. Mol Immunol. 2014;62(2):296\u2013304.","journal-title":"Mol Immunol"},{"issue":"1","key":"2632_CR223","doi-asserted-by":"publisher","first-page":"5850","DOI":"10.1038\/s41467-020-19650-8","volume":"11","author":"D Huang","year":"2020","unstructured":"Huang D, Tran JT, Olson A, Vollbrecht T, Tenuta M, Guryleva MV, et al. Vaccine elicitation of HIV broadly neutralizing antibodies from engineered B cells. Nat Commun. 2020;11(1):5850.","journal-title":"Nat Commun"},{"issue":"3","key":"2632_CR224","doi-asserted-by":"publisher","first-page":"755","DOI":"10.4049\/jimmunol.2100340","volume":"207","author":"AM Jeske","year":"2021","unstructured":"Jeske AM, Boucher P, Curiel DT, Voss JE. Vector strategies to actualize B cell\u2013based gene therapies. J Immunol. 2021;207(3):755\u201364.","journal-title":"J Immunol"},{"issue":"6","key":"2632_CR225","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1182\/bloodadvances.2020003792","volume":"5","author":"N Ueda","year":"2021","unstructured":"Ueda N, Cahen M, Danger Y, Moreaux J, Sirac C, Cogn\u00e9 M. Immunotherapy perspectives in the new era of B-cell editing. Blood Adv. 2021;5(6):1770\u20139.","journal-title":"Blood Adv"},{"issue":"1","key":"2632_CR226","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13045-025-01701-6","volume":"18","author":"H Qin","year":"2025","unstructured":"Qin H, Zhou Z, Shi R, Mai Y, Xu Y, Peng F, et al. Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects. J Hematol Oncol. 2025;18(1):62.","journal-title":"J Hematol Oncol"},{"key":"2632_CR227","doi-asserted-by":"crossref","unstructured":"Cooper GM, Adams K. The cell: a molecular approach. Oxford University Press; 2022.","DOI":"10.1093\/hesc\/9780197583746.001.0001"},{"key":"2632_CR228","doi-asserted-by":"publisher","DOI":"10.3390\/cells14050320","author":"Bohan Zhang","year":"2025","unstructured":"Zhang B, Wu J, Jiang H, Zhou M. Strategies to overcome antigen heterogeneity in CAR-T cell therapy. Cells. 2025;14(5):1-22. https:\/\/doi.org\/10.3390\/cells14050320","journal-title":"Cells"},{"issue":"1","key":"2632_CR229","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41392-024-01851-y","volume":"9","author":"X Chu","year":"2024","unstructured":"Chu X, Tian W, Ning J, Xiao G, Zhou Y, Wang Z, et al. Cancer stem cells: advances in knowledge and implications for cancer therapy. Signal Transduct Target Therapy. 2024;9(1):170.","journal-title":"Signal Transduct Target Therapy"},{"key":"2632_CR230","doi-asserted-by":"publisher","first-page":"216894","DOI":"10.1016\/j.canlet.2024.216894","volume":"591","author":"M El-Tanani","year":"2024","unstructured":"El-Tanani M, Rabbani SA, Babiker R, Rangraze I, Kapre S, Palakurthi SS, et al. Unraveling the tumor microenvironment: insights into cancer metastasis and therapeutic strategies. Cancer Lett. 2024;591:216894.","journal-title":"Cancer Lett"},{"key":"2632_CR231","first-page":"21","volume":"8","author":"J Yu","year":"2025","unstructured":"Yu J, Kong X, Feng Y. Tumor microenvironment-driven resistance to immunotherapy in non-small cell lung cancer: strategies for Cold-to-Hot tumor transformation. Cancer Drug Resist. 2025;8:21.","journal-title":"Cancer Drug Resist"},{"key":"2632_CR232","doi-asserted-by":"publisher","first-page":"115569","DOI":"10.1016\/j.biopha.2023.115569","volume":"167","author":"P Zhang","year":"2023","unstructured":"Zhang P, Wang Y, Miao Q, Chen Y. The therapeutic potential of PD-1\/PD-L1 pathway on immune-related diseases: based on the innate and adaptive immune components. Biomed Pharmacother. 2023;167:115569.","journal-title":"Biomed Pharmacother"},{"key":"2632_CR233","doi-asserted-by":"publisher","first-page":"1200646","DOI":"10.3389\/fonc.2023.1200646","volume":"13","author":"P Czajka-Francuz","year":"2023","unstructured":"Czajka-Francuz P, Prendes MJ, Mankan A, Quintana \u00c1, Pabla S, Ramkissoon S, et al. Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapy. Front Oncol. 2023;13:1200646.","journal-title":"Front Oncol"},{"key":"2632_CR234","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.omto.2022.03.009","volume":"25","author":"LA Kankeu Fonkoua","year":"2022","unstructured":"Kankeu Fonkoua LA, Sirpilla O, Sakemura R, Siegler EL, Kenderian SS. CAR T cell therapy and the tumor microenvironment: current challenges and opportunities. Mol Ther Oncolytics. 2022;25:69\u201377.","journal-title":"Mol Ther Oncolytics"},{"issue":"5","key":"2632_CR235","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41419-024-06697-4","volume":"15","author":"Z Mai","year":"2024","unstructured":"Mai Z, Lin Y, Lin P, Zhao X, Cui L. Modulating extracellular matrix stiffness: a strategic approach to boost cancer immunotherapy. Cell Death Dis. 2024;15(5):307.","journal-title":"Cell Death Dis"},{"issue":"5","key":"2632_CR236","doi-asserted-by":"publisher","first-page":"189162","DOI":"10.1016\/j.bbcan.2024.189162","volume":"1879","author":"K Kang","year":"2024","unstructured":"Kang K, Lin X, Chen P, Liu H, Liu F, Xiong W, et al. T cell exhaustion in human cancers. Biochim Et Biophys Acta (BBA)-Reviews Cancer. 2024;1879(5):189162.","journal-title":"Biochim Et Biophys Acta (BBA)-Reviews Cancer"},{"key":"2632_CR237","doi-asserted-by":"publisher","first-page":"111093","DOI":"10.1016\/j.intimp.2023.111093","volume":"125","author":"A Sayadmanesh","year":"2023","unstructured":"Sayadmanesh A, Yekehfallah V, Valizadeh A, Abedelahi A, Shafaei H, Shanehbandi D, et al. Strategies for modifying the chimeric antigen receptor (CAR) to improve safety and reduce toxicity in CAR T cell therapy for cancer. Int Immunopharmacol. 2023;125:111093.","journal-title":"Int Immunopharmacol"},{"issue":"26","key":"2632_CR238","first-page":"3321","volume":"127","author":"JN Brudno","year":"2016","unstructured":"Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. J Am Soc Hematol. 2016;127(26):3321\u201330.","journal-title":"J Am Soc Hematol"},{"key":"2632_CR239","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.reth.2025.06.017","volume":"30","author":"FA Kakroodi","year":"2025","unstructured":"Kakroodi FA, Khodadoust E, Alizadeh M, Tehrani RSH, Sarabi PA, Rahmanian M, et al. Current challenges and future directions of ATMPs in regenerative medicine. Regenerative Therapy. 2025;30:358\u201370.","journal-title":"Regenerative Therapy"},{"key":"2632_CR240","doi-asserted-by":"publisher","first-page":"1407143","DOI":"10.3389\/fonc.2024.1407143","volume":"14","author":"N Puebla-Osorio","year":"2024","unstructured":"Puebla-Osorio N, Fowlkes NW, Barsoumian HB, Xega K, Srivastava G, Kettlun-Leyton C, et al. Enhanced tumor control and survival in preclinical models with adoptive cell therapy preceded by low-dose radiotherapy. Front Oncol. 2024;14:1407143.","journal-title":"Front Oncol"},{"key":"2632_CR241","doi-asserted-by":"publisher","first-page":"1187850","DOI":"10.3389\/fimmu.2023.1187850","volume":"14","author":"CJ Sailer","year":"2023","unstructured":"Sailer CJ, Hong Y, Dahal A, Ryan AT, Mir S, Gerber SA, et al. PD-1(Hi) CAR-T cells provide superior protection against solid tumors. Front Immunol. 2023;14:1187850.","journal-title":"Front Immunol"},{"key":"2632_CR242","doi-asserted-by":"publisher","first-page":"1140541","DOI":"10.3389\/fimmu.2023.1140541","volume":"14","author":"AX Wang","year":"2023","unstructured":"Wang AX, Ong XJ, D\u2019Souza C, Neeson PJ, Zhu JJ. Combining chemotherapy with CAR-T cell therapy in treating solid tumors. Front Immunol. 2023;14:1140541.","journal-title":"Front Immunol"},{"key":"2632_CR243","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/jcm13216537","volume":"13","author":"P Garg","year":"2024","unstructured":"Garg P, Pareek S, Kulkarni P, Horne D, Salgia R, Singhal SS. Next-Generation immunotherapy: advancing clinical applications in cancer treatment. J Clin Med. 2024;13:21.","journal-title":"J Clin Med"},{"key":"2632_CR244","doi-asserted-by":"publisher","DOI":"10.1172\/jci162088","author":"Sumedha Roy","year":"2023","unstructured":"Roy S, Fitzgerald K, Lalani A, Lai CW, Kim A, Kim J et al. Autonomous IL-36R signaling in neutrophils activates potent antitumor effector functions. J Clin Invest. 2023;133(12): 1-17. https:\/\/doi.org\/10.1172\/jci162088","journal-title":"journal of clinical investigation"},{"issue":"1","key":"2632_CR245","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41417-021-00303-x","volume":"29","author":"K Kohli","year":"2022","unstructured":"Kohli K, Pillarisetty VG, Kim TS. Key chemokines direct migration of immune cells in solid tumors. Cancer Gene Ther. 2022;29(1):10\u201321.","journal-title":"Cancer Gene Ther"},{"issue":"11","key":"2632_CR246","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1038\/s41590-019-0512-0","volume":"20","author":"LP Andrews","year":"2019","unstructured":"Andrews LP, Yano H, Vignali DA. Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups. Nat Immunol. 2019;20(11):1425\u201334.","journal-title":"Nat Immunol"},{"key":"2632_CR247","doi-asserted-by":"publisher","first-page":"1535647","DOI":"10.3389\/fimmu.2024.1535647","volume":"15","author":"GF Soko","year":"2024","unstructured":"Soko GF, Kosgei BK, Meena SS, Ng YJ, Liang H, Zhang B, et al. Extracellular matrix re-normalization to improve cold tumor penetration by oncolytic viruses. Front Immunol. 2024;15:1535647.","journal-title":"Front Immunol"},{"issue":"9","key":"2632_CR248","doi-asserted-by":"publisher","first-page":"e1901058","DOI":"10.1002\/adhm.201901058","volume":"9","author":"A Farzin","year":"2020","unstructured":"Farzin A, Etesami SA, Quint J, Memic A, Tamayol A. Magnetic nanoparticles in cancer therapy and diagnosis. Adv Healthc Mater. 2020;9(9):e1901058.","journal-title":"Adv Healthc Mater"},{"issue":"1","key":"2632_CR249","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12951-019-0520-0","volume":"17","author":"L Sanz-Ortega","year":"2019","unstructured":"Sanz-Ortega L, Portilla Y, P\u00e9rez-Yag\u00fce S, Barber DF. Magnetic targeting of adoptively transferred tumour-specific nanoparticle-loaded CD8\u2009+\u2009T cells does not improve their tumour infiltration in a mouse model of cancer but promotes the retention of these cells in tumour-draining lymph nodes. J Nanobiotechnol. 2019;17(1):87.","journal-title":"J Nanobiotechnol"},{"key":"2632_CR250","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3389\/fphar.2014.00254","volume":"5","author":"BS Jones","year":"2014","unstructured":"Jones BS, Lamb LS, Goldman F, Di Stasi A. Improving the safety of cell therapy products by suicide gene transfer. Front Pharmacol. 2014;5:254.","journal-title":"Front Pharmacol"},{"key":"2632_CR251","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.omto.2022.10.011","volume":"27","author":"X Wu","year":"2022","unstructured":"Wu X, Matosevic S. Gene-edited and CAR-NK cells: opportunities and challenges with engineering of NK cells for immunotherapy. Mol Therapy-Oncolytics. 2022;27:224\u201338.","journal-title":"Mol Therapy-Oncolytics"},{"key":"2632_CR252","doi-asserted-by":"publisher","first-page":"101241","DOI":"10.1016\/j.blre.2024.101241","volume":"68","author":"AK Arunachalam","year":"2024","unstructured":"Arunachalam AK, Gr\u00e9goire C, de Oliveira BC, Melenhorst JJ. Advancing CAR T-cell therapies: preclinical insights and clinical translation for hematological malignancies. Blood Rev. 2024;68:101241.","journal-title":"Blood Rev"},{"key":"2632_CR253","doi-asserted-by":"publisher","first-page":"113561","DOI":"10.1016\/j.jconrel.2025.02.057","volume":"381","author":"A Melocchi","year":"2025","unstructured":"Melocchi A, Schmittlein B, Sadhu S, Nayak S, Lares A, Uboldi M, et al. Automated manufacturing of cell therapies. J Controlled Release. 2025;381:113561.","journal-title":"J Controlled Release"},{"key":"2632_CR254","doi-asserted-by":"publisher","first-page":"1586912","DOI":"10.3389\/fbioe.2025.1586912","volume":"13","author":"N Kok","year":"2025","unstructured":"Kok N, Dekkers Z, Loos A, Bos T, van den Broek P, Post I, et al. Closed-system manufacturing of therapeutic NK cells using automated cell enrichment and concentration processes enables scalable, robust and costeffective solutions. Front Bioeng Biotechnol. 2025;13:1586912.","journal-title":"Front Bioeng Biotechnol"},{"issue":"1","key":"2632_CR255","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/imr.13249","volume":"318","author":"RS Goodman","year":"2023","unstructured":"Goodman RS, Jung S, Balko JM, Johnson DB. Biomarkers of immune checkpoint inhibitor response and toxicity: challenges and opportunities. Immunol Rev. 2023;318(1):157\u201366.","journal-title":"Immunol Rev"},{"key":"2632_CR256","doi-asserted-by":"publisher","first-page":"627764","DOI":"10.3389\/fimmu.2021.627764","volume":"12","author":"R Hong","year":"2021","unstructured":"Hong R, Hu Y, Huang H. Biomarkers for chimeric antigen receptor T cell therapy in acute lymphoblastic leukemia: prospects for personalized management and prognostic prediction. Front Immunol. 2021;12:627764.","journal-title":"Front Immunol"},{"issue":"5","key":"2632_CR257","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3390\/vaccines13050521","volume":"13","author":"J Hu","year":"2025","unstructured":"Hu J, Jin M, Feng W, Nassif-Rausseo B, Reuben A, Ma C, et al. Clinical and fundamental research progressions on Tumor-Infiltrating lymphocytes therapy in cancer. Vaccines. 2025;13(5):521.","journal-title":"Vaccines"},{"key":"2632_CR258","doi-asserted-by":"publisher","first-page":"1583116","DOI":"10.3389\/fimmu.2025.1583116","volume":"16","author":"L-Y Cao","year":"2025","unstructured":"Cao L-Y, Zhao Y, Chen Y, Ma P, Xie J-C, Pan X-M, et al. CAR-T cell therapy clinical trials: global progress, challenges, and future directions from ClinicalTrials. Gov insights. Front Immunol. 2025;16:1583116.","journal-title":"Front Immunol"},{"key":"2632_CR259","doi-asserted-by":"publisher","first-page":"1487782","DOI":"10.3389\/fimmu.2024.1487782","volume":"15","author":"J Li","year":"2024","unstructured":"Li J, Zhang Y, Fu T, Xing G, Cai H, Li K, et al. Clinical advances and challenges associated with TCR-T cell therapy for cancer treatment. Front Immunol. 2024;15:1487782.","journal-title":"Front Immunol"},{"key":"2632_CR260","doi-asserted-by":"publisher","first-page":"117858","DOI":"10.1016\/j.biopha.2025.117858","volume":"184","author":"M Sheykhhasan","year":"2025","unstructured":"Sheykhhasan M, Ahmadieh-Yazdi A, Heidari R, Chamanara M, Akbari M, Poondla N, et al. Revolutionizing cancer treatment: the power of dendritic cell-based vaccines in immunotherapy. Biomed Pharmacother. 2025;184:117858.","journal-title":"Biomed Pharmacother"},{"issue":"10","key":"2632_CR261","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00432-025-06329-0","volume":"151","author":"W Wei","year":"2025","unstructured":"Wei W, Wu X, Wang L, Zhang J, Zhang C, Wang D. Mapping the global clinical landscape of NK cell therapies for solid tumors: an analysis based on the ClinicalTrials. Gov for the 2005\u20132024 period. J Cancer Res Clin Oncol. 2025;151(10):1\u20134.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2632_CR262","doi-asserted-by":"publisher","unstructured":"Biederst\u00e4dt A, Rezvani K. Engineered natural killer cells for cancer therapy. Cancer Cell. 2025. https:\/\/doi.org\/10.1016\/j.ccell.2025.09.013","DOI":"10.1016\/j.ccell.2025.09.013"},{"issue":"6","key":"2632_CR263","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.3390\/cells10061329","volume":"10","author":"Z Ingram","year":"2021","unstructured":"Ingram Z, Madan S, Merchant J, Carter Z, Gordon Z, Carey G, et al. Targeting natural killer T cells in solid malignancies. Cells. 2021;10(6):1329.","journal-title":"Cells"},{"issue":"1","key":"2632_CR264","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s12943-025-02386-8","volume":"24","author":"SS Azeez","year":"2025","unstructured":"Azeez SS, Yashooa RK, Smail SW, Salihi A, Ali AS, Mamand S, et al. Advancing CAR-based cell therapies for solid tumours: challenges, therapeutic strategies, and perspectives. Mol Cancer. 2025;24(1):191.","journal-title":"Mol Cancer"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-025-02632-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-025-02632-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-025-02632-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T14:02:46Z","timestamp":1770040966000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12964-025-02632-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,31]]},"references-count":264,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2632"],"URL":"https:\/\/doi.org\/10.1186\/s12964-025-02632-y","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,31]]},"assertion":[{"value":"26 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"73"}}